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RNA polymerase II (Pol II) is the central enzyme that transcribes eukaryotic protein-coding 
genes to produce mRNA. The mushroom toxin α-amanitin binds Pol II and inhibits 
transcription at the step of RNA chain elongation. Pol II from yeast binds α-amanitin with 
micromolar affinity, whereas metazoan Pol II enzymes exhibit nanomolar affinities. Here, I 
present the high resolution cryo-EM structure of α-amanitin bound to and inhibited by its 
natural target, the mammalian Pol II elongation complex. The structure revealed that the 
toxin is located in a pocket previously identified in yeast Pol II but forms additional contacts 
with metazoan-specific residues, which explains why its affinity to mammalian Pol II is 
∼3000 times higher than for yeast Pol II. The work provides the structural basis for the 
inhibition of mammalian Pol II by the natural toxin α-amanitin and highlights that cryo-EM is 
well suited to studying interactions of a small molecule with its macromolecular target. 
 
Chapter 2 
Transcription termination is coupled to pre-mRNA 3’ processing. In mammals, more than 
twenty protein factors are involved in these processes. The definition of the cleavage site 
needs not only protein factors but also specific cis sequence elements on pre-mRNA. The 
best known cis elements include the polyadenylation signal (PAS, featuring the base 
sequence AAUAAA), the upstream elements (USE, featuring the base sequence UGUA) and 
downstream elements (DSE, characteristically GU/U rich), which are bound by the cleavage 
and polyadenylation (CPSF) complex, the cleavage factor I (CFI) complex and the cleavage 
stimulation factor (CstF) complex respectively. Other termination/3’ processing factors 
include cleavage factor II (CFII), polyadenylation polymerase (PAP), polyadenylate-binding 
nuclear protein 1 (PABPN1), Pol II carboxy terminal domain (CTD), symplekin (SYMPK), as 
well as some kinases and phosphatases and other factors. Based on the functional 
differences, CPSF complex is divided into two modules: the polymerase module, which is 
composed of CPSF160, WDR33, CPSF30 and Fip1, and the nuclease module which is 
composed of CPSF100 and CPSF73. The polymerase module binds specifically to PAS site 
while the nuclease module is responsible for the cleavage of pre-mRNA. CPSF73 is the 
endonuclease. After cleavage, a polyadenylic acid tail (poly(A) tail) is added to the 3’ end of 
RNA by PAP. In this work, I managed the expression and purification of the sub-complexes 
CFI, CFII, CstF, CPSF polymerase module and CPSF nuclease module plus symplekin. The CstF 
complex can be crystallized but the diffraction of the crystal was not good enough to solve 
the structure yet. The CPSF polymerase module and nuclease module plus symplekin can 
form a stable complex which is suitable for cryo-EM structure analysis. From the initial data 
processing, the extra density in addition to the polymerase module can be seen. However, 
the resolution of the density map needs to be improved by further processing. 
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1.1 The central dogma and RNA polymerases 
Genetic information defines various species and their characteristics. In living organisms, 
genetic information is normally stored in the form of DNA sequences. To make the genetic 
information function in the organisms and to keep the species characteristic constant, two 
more biopolymers are necessary, which are RNA and protein. The DNA sequence is used as a 
template for the synthesis of RNA by a process named transcription, and RNA sequence 
directs the synthesis of proteins by a process named as translation. This flow of genetic 
information is the basic outline of the central dogma of molecular biology (Crick, 1970). 
However, the central dogma also includes DNA replication, where the DNA molecule can 
replicate itself to provide genetic material for progeny (Meselson and Stahl, 1958). Further 
supplementary to the central dogma are special forms of information transfer from RNA to 
DNA and from RNA to RNA, which normally happens in viruses and are called reverse 
transcription and RNA replication respectively (Ahlquist, 2002; Temin and Mizutani, 1970). 
Additionally, prions can propagate themselves in host cells which are the only protein to 
protein information encoding known so far (Prusiner, 1991). 
RNA polymerase, abbreviated RNAP, is one kind of enzyme that synthesizes RNA from a DNA 
template. RNAP exists in both viruses and living organisms. Depending on the species, RNAP 
might be a single subunit enzyme (Cermakian et al., 1997) or a protein complex with several 
subunits (Werner and Grohmann, 2011). In Prokaryotes and archaea, there is only one kind 
of RNAP that transcribes all kinds of RNAs, whereas in eukaryotes, there are three different 
kinds of RNA polymerases (Roeder and Rutter, 1969; Sentenac, 1985). RNA polymerase I (Pol 
I) is responsible for the transcription of ribosome RNA (rRNA)(Grummt, 2003) except for 5S 
rRNA, which is transcribed by RNA polymerase II (Pol II). RNA polymerase III (Pol III) 
synthesizes small RNAs like U6 spliceosomal small nuclear RNA (snRNA), transfer RNA 
(tRNAs), adenovirus-associated RNA (VA-RNA) and 7SK RNAs (Geiduschek and Kassavetis, 
2001). Pol II is responsible for synthesizing all protein-coding RNAs and most non-coding 
RNAs, including small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), microRNAs 
(miRNAs), cryptic unstable transcripts (CUTs) and stable unannotated transcripts (SUTs)(Liu 
et al., 2013). In eukaryotes, the protein coding genes are transcribed by Pol II as precursor 
message RNAs (pre-mRNAs) which need to be further processed to become mature mRNA. 
Further processing of pre-mRNA includes 5’ capping, 3’ polyadenylation and intron splicing 
(Hirose and Manley, 2000). The mature mRNA is more stable and can be exported from 
nuclei to the cytoplasm for translation. In plants, there are two more RNA polymerases, Pol 
IV and Pol V, which are thought to generate non-coding RNA transcripts and mediate gene-
silencing processes (Ream et al., 2009; Zhang et al., 2007). As mentioned before, bacteria 
has only one type of RNA polymerase which is responsible for the transcription of all kinds of 
RNAs (Darst et al., 1989). RNAP in archaea varies in different species and shares similar 
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features with both eukaryotic RNAP and bacterial RNAP. Most of the RNAP known so far in 
archaea are composed of more than ten subunits and with an overall shape that is quite 
similar to their eukaryotic counterpart (Hirata et al., 2008). On the other hand, the archaeal 
RNAP is normally responsible for the transcription of all kinds of RNAs in cells, which is 
similar to the bacterial RNAP. 
The bacterial RNAP is the simplest one among the three kingdoms of life, the core enzyme is 
composed of five subunits: two copies of α, ß, ß’ and ω (Ebright, 2000; Mathew and 
Chatterji, 2006). The sixth subunit σ is thought to be a complementary subunit which helps 
to recognize the promoter and start promoter-specific transcription (Kang et al., 1997). 
RNAP structure varies in different archaeal species. In the known archaeal RNAPs, the 
protein complex consists of 11 to 13 subunits depending on the species. Taking the 
Sulfolobus solfataricus RNAP as an example, the crystal structure of S. solfataricus RNAP was 
solved in 2008 (Hirata et al., 2008) and it consists of 13 subunits which include RpoA’, A’’, 
RpoB, D, K, L, F, H, E, G, N, P and Rpo13. Rpo13 exists only in some archaea species. The 
overall shape is similar to Pol II in eukaryotes with a ‘crab’ like shape. RpoE/F makes up the 
stalk of the polymerase. However, there is one difference between Pol II and archaea RNAP. 
In archaea RNAP, the biggest subunit RpoA is divided into two polypeptides, which are 
encoded by two different genes and connected by the ‘foot’ domain, while in Pol II, the 
corresponding subunit Rpb1 is a single subunit encoded by one gene. 
 As mentioned before, there are three different RNA polymerases in eukaryotes which are 
responsible for the transcription of different types of RNA. All three RNA polymerases (Pol I, 
Pol II and Pol III) contain a ‘conservation core’ which was conserved from bacteria to 
eukaryotes. Yeast Pol I is a 14-subunit complex with a molecular weight of 590kDa. With 
regards to subunit composition, Pol I contains a Pol II like core which is composed of five 
subunits (A190, A135, AC40, AC19 and A12.2), five common subunits (Rpb5, Rpb6, Rpb8, 
Rpb10 and Rpb12) which are the same as Pol II and two specific heterodimeric sub-
complexes: A14–A43 and A49–A34.5. A190 and A135 are the two biggest subunits which are 
corresponding to Rpb1 and Rpb2 respectively (Engel et al., 2013). Pol III is the largest of the 
three RNA polymerases, which contains 17 subunits and has a total molecular weight of 
700kDa. C160 and C128 are the two biggest subunits which correspond to Rpb1 and Rpb2 
respectively. The other subunits include the core subunits ABC27, ABC23, ABC14.5, ABC10α 
and ABC10β which are common between Pol I, Pol II and Pol III, subunits AC40 and AC19 
shared by Pol I and Pol III and subunits C25, C17, C11, C53, C37, C82, C34, C31. C53 and C37 
form the TFIIF similar complex and C11 is a termination factor for Pol III transcription (Han et 
al., 2018). Pol II is the best studied RNAP both in yeast and in mammals, which might be 
attributed to the fact that it is responsible for the transcription of all protein coding genes. 
Pol II is a 500kDa complex which is composed of the ten-subunit core (Rpb1 to Rpb12) and 
the Rpb4/7 stalk. Rpb1 and Rpb2 form a clamp with other subunits arraying around the 
periphery (Cramer et al., 2000). The active center is located in the Rpb1-Rpb2 cleft with a 
divalent ion of Mg2+ for activity (Armache et al., 2003). The Rpb4/7 stalk is highly flexible in 
Pol II. The structure of mammalian Pol II is quite similar to its yeast counterpart except for 
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some residue differences (Bernecky et al., 2016b). Different groups of factors are necessary 
for initiation, elongation and termination during Pol II transcription. 
Human Gdown1 is the product of the POLR2M gene, the molecular weight is 42 kDa. In some 
early studies, Gdown1 was thought to be the 13th subunit of Pol II in metazoans because it is 
associated tightly with Pol II during purification (Hu et al., 2006). The study of Gdown1 also 
showed that Gdown1 holds the paused Pol II by competing for the same binding position on 
the initiation complex with TFIIF (Wu et al., 2012). However, the Gdown1 ‘paused’ Pol II can 
be released by mediator and mediator dependent regulation is enforced by Gdown1 (Jishage 
et al., 2012). 
1.2 α-amanitin - the cyclic Octapeptide from toxic mushrooms 
1.2.1 Research history of amanitin 
Macroscopic life is composed of fungi, plants, animals and human beings. Human beings are 
at the higher level of food chains, which means human beings always have more access to 
food choices. However, not all ‘plants in the big garden’ are edible. All animals have unique 
ways to fight for survival, as do plants. Plants cannot move and do real ‘fighting’, but they 
also found their own ways to protect themselves during evolution, just like some of the 
mushrooms. Even though they have pretty colors and can offer animals and people nutrition 
and energy, they secrete highly toxic chemicals which may cause severe physical injuries or 
even death after ingestion (Wieland, 1986). 
The study of mushroom toxins started from the beginning of 20th century (Ford, 1907), when 
Hermann Schlesinger and William W. Ford tried to purify the toxic factors from amanita 
phalioides mushrooms. They managed to purify a heat-resistant substance and named it 
Amanita-toxin. Even with very crude methods, they managed to purify the toxin to a content 
of about 10% purity. With preliminary chemical studies, they identified the toxic chemical as 
an ‘aromatic phenol combined with an amine group that it readily forms an indol or pyrrol 
ring’ instead of a beta proteid, a glucoside, or an alkaloid. In 1937, Feodor Lynen and Ulrich 
Wieland succeeded in crystallizing the Amanita-toxin (Wieland and Hallermayer, 1941). 
Rudolf Hallermayer also described the crystallization of amanitin in his PhD thesis in 1940. 
However, because of the high toxicity and low purity, it took another fifty years for people to 
finally solve the amanitin structure and learn its toxicological mechanism (Wienland and 
Faulstich, 1991). 
1.2.2 The structure of α-amanitin 
The amatoxins form a family. The early method defined the name based on electrophoresis. 
The neutral compound was called α-amanitin and the acidic one was named β-amanitin 
(Wieland, 1948). γ- and ε-amanitin was also discovered and isolated afterwards as well as 
some non-poisonous components like amanullin and amaninamide (Buku et al., 1980; 
Cochet-Meilhac and Chambon, 1974).  
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α-amanitin is a cyclic peptide which is composed of eight amino acid residues (Hatzoglou et 
al., 1985). The linkage of 6-hydroxytrytophan and cysteine forms an inner ring (Michelot and 
Labia, 1988). There are several modified amino acid side chains within the α-amanitin 
molecule, which include hydroxyl proline at position 4, 4,5-dihydroxy-isoleucine and 6-
hydroxy-2-mercapto-L- Tryptophan (Figure 1.1). These modified amino acid residue side 
chains help α-amanitin bind to RNA polymerase and inhibit transcription in cells (Wieland et 
al., 1983; Zanotti et al., 1989). These three modified side chains significantly affect the 
binding affinity of α-amanitin to different RNA polymerases (Figure 1.1). 
 
Figure 1.1: schematic diagram of α-amanitin. The three side chains which are important for 
RNAP binding and activity are highlighted with black circles. 
1.2.3 The toxicity of α-amanitin and Pol II 
α-amanitin is found in several species of mushrooms from the mushroom genus Amanita. 
Ingestion of mushrooms that contain α-amanitin results in four stages of toxicity symptoms 
(Mas, 2005; Yilmaz et al., 2015). The first stage of symptoms normally appears 8 to 10 hours 
after the intake. In this stage, the patient suffers from severe digestive system reactions like 
nausea and vomiting. Normally a pseudo-recovery stage comes after the first stage which 
shows almost no symptoms. This makes the diagnosis and emergency treatment difficult 
because this pseudo-recovery might mislead both the patient and the clinician. However, in 
the third stage, which normally appears on day three after ingestion, liver and kidney failure 
becomes obvious, which could be attributed to affected enterohepatic circulation. If no 
therapy is executed from this stage, the patient would die of massive liver necrosis and 
kidney failure in 5 to 12 days (Mas, 2005). 
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The toxicity of α-amanitin comes from its specific binding to Pol II and the inhibition of 
transcription in cells (Fiume and Stirpe, 1966). The binding affinity of α-amanitin to Pol I and 
Pol III is much weaker than to Pol II. Pol I is totally insensitive to it, and Pol III is inhibited only 
at a very high concentration in animals. The binding affinity also varies between virus, 
bacterias, yeasts and mammals, with the binding affinity more than one thousand times 
higher in mammals than in yeast (Cochet-Meilhac et al., 1974; Wienland and Faulstich, 
1991)(Table 1.1). 
 
Table 1.1: α-amanitin binding affinity varies in different organisms. The binding affinity to 
Pol II is ~1000 times higher in mammals than in yeast (see the red rectangle box). Table was 
adapted from T. Wieland and H. Faulstich., Fifty years of amanitin, 1991 
1.3 Transcription elongation and α-amanitin inhibition in eukaryotes  
1.3.1 An overview of transcription cycle 
In Eukaryotes, transcription commences with the recognition of the promoter by initiation 
factors. The assembly of the initiation factors and RNA polymerase forms the pre-initiation 
complex (Sainsbury et al., 2015). In Pol II transcription initiation, the general initiation factors 
play important roles. The general transcription factors include TFIIA, TFIIB, TFIID, TFIIE, TFIIF 
and TFIIH. TFIID itself is a big protein complex with a total size of 1.2 MDa. It is composed of 
TATA box binding protein (TBP) and 13–14 TBP associated factors (TAFs)(Bieniossek et al., 
2013). To initiate the transcription, TBP binds to the promoter DNA and bends the DNA by 
90 degrees. The whole TFIID factor is responsible for the specific recognition of promoters 
and DNA bending for initiation (Louder et al., 2016). TFIIA is Pol II transcription specific and 
helps the binding of TBP to DNA (Hoiby et al., 2007). The opening of double stranded DNA 
needs the cooperation of TFIIB, TFIIE and TFIIH. The structure of the TFIIB-Pol II complex 
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elucidated that TFIIB functions in Pol II recruitment, DNA bending and opening, initiation of 
RNA synthesis and transition from initiation to elongation (Sainsbury et al., 2013). The 
promoter opening of DNA requires TFIIE and TFIIH. TFIIE is composed of the TFIIE α and TFIIE 
β subunits and is responsible for the anchoring of the TFIIH kinase module (CAK) to the 
preinitiation complex. TFIIE also facilitates the recruitment of TFIIH to the initiation complex 
and stimulates the activity of TFIIH (Miwa et al., 2016).  TFIIH is a complex of 10 subunits and 
consists of both ATPase and kinase activity. The ATPase activity offers energy during DNA 
opening by hydrolysis of ATP (Schilbach et al., 2017). TFIIF is a three-subunit protein complex 
that associates with Pol II. TFIIF influences selection of transcription start site, stabilizes the 
initiation complex (ITC) and assists early RNA synthesis (Robert et al., 1998). After the 
assembly of the ITC, transcription starts. 
However, before going into processive elongation, Pol II would normally suffer from a 
‘promoter-proximal’ pausing, which means most of the initiation factors have left and Pol II 
stops at the promoter-proximal region (Adelman and Lis, 2012). The ‘paused’ Pol II is 
normally stabilized by the protein complexes DRB sensitivity-inducing factor (DSIF) and 
negative elongation factor (NELF)(Vos et al., 2018b). The formation of the activated Pol II 
elongation complex requires two more elongation factors and one kinase, which are the Pol 
II associated factor (PAF), SPT6 and the positive transcription elongation factor (P-TEFb). PAF 
is a protein complex composed of 6 subunits (Paf1, Rtf1, Ski8, Cdc73, CTR9 and Leo1) in 
human (Vos et al., 2018a). In the pause-release transition, PAF complex takes the place of 
NELF on Pol II, and the elongation factor Spt6 binds to the CTD linker of RPB1 and helps to 
release the paused Pol II. The release of Pol II also needs P-TEFb, which is a cyclin-dependent 
kinase composed of CDK9 and cyclin T. The phosphorylation of both CTD and elongation 
factors stimulate Pol II release and elongation (Vos et al., 2018a).  
During elongation, Pol II walks along the DNA template and transcribes pre-mRNA with the 
binding of super elongation factors (Luo et al., 2012). After walking over the poly(A) signal, 
Pol II suffers from another pause, where the elongation factors are replaced by termination 
factors (Glover-Cutter et al., 2008). The cleavage at the 3’ end of the pre-mRNA induces the 
termination mechanism, which results in the release of both Pol II and RNA from the 
template DNA (Richardson, 1993), a process known as transcription termination. 
1.3.2 Nucleotide addition cycle and α-amanitin inhibition 
As mentioned in the last paragraph, during transcription elongation, Pol II moves along the 
DNA template and synthesizes a complementary pre-mRNA chain. Extension of the RNA 
chain is achieved by the nucleotide addition cycle (NAC) (Cramer, 2007). NAC is a highly 
coordinated process of several elements in the active center of Pol II, which includes the 
bridge helix, the trigger loop (Wang et al., 2006) and the central magnesium ions. The trigger 
loop is a highly mobile loop that undergoes folding to catalyze the extension of the RNA 
chain, and is also important for the translocation of nucleic acids to the next DNA template 




 Figure 1.2: Nucleotide addition cycle. Diagram was adapted from Florian Brueckner., et al 
2008 
During the NAC, a nucleoside triphosphate binds to the transcribing elongation complex (EC), 
which is formed by Pol II, DNA and the elongating RNA (Gnatt et al., 2001). The insertion and 
catalytic addition of the nucleotide to the 3’ end of the elongating RNA would lead to the 
formation of a pyrophosphate ion. The release of the pyrophosphate leads to the pre-
translocation, which means that the newly added nucleotides at the 3’-terminal side still 
stays at the substrate site and a new free nucleotide is not allowed to incorporate. To free 
the active center out for the next NTP binding, the DNA and RNA molecule slide along Pol II 
and translocate with the help of bridge helix and trigger loop (Naji et al., 2008). However, if 
Pol II was bound by α-amanitin at its active center at this stage, the small cyclic peptides 
would trap the bridge helix and the trigger loop and prevent Pol II translocation, which ends 
8 
 
up with an abortive transcription and death of cells because of transcription deficiency 
(Figure 1.2)(Brueckner and Cramer, 2008). 
 In 2002, the first crystal structure of yeast Pol II-α-amanitin was solved and the binding 
pocket of α-amanitin on Pol II was defined (Bushnell et al., 2002). In 2008, Florian Brueckner 
and Patrick Cramer solved the crystal structure of yeast Pol II elongation complex inhibited 
by α-amanitin (Brueckner and Cramer, 2008). In this structure, the trigger loop was locked by 
α-amanitin in a very special translocation intermediate state, which was defined as ‘wedged 
trigger loop’. The wedged trigger loop helped to elucidate the translocation process in NAC. 
The binding pocket was also better defined in this structure. However, the binding affinity of 
α-amanitin to mammalian Pol II is more than 1000 times higher than yeast (Table 
1.1)(Wienland and Faulstich, 1991), and also, animals and human beings are normally the 
targets that the mushrooms need to protect themselves from. As yeasts and mushrooms 
both belong to the fungus family, yeast should not be the natural target of α-amanitin. To 
figure out why the binding affinity is much higher in its natural target and whether the 
binding position is the same in its natural target, we decided to solve the structure of 
mammalian Pol II bound by α-amanitin in this study. As cryo-EM is a well-known method for 
solving protein structures nowadays, we were also curious whether it is possible to solve a 

















2 Materials and Methods 
2.1 Materials 
 
Name                                Composition                                Application 
 
100 × PI                                   1mM leupeptin                                    Protein purification 
                                                 2mM pepstatin A  
                                                 100mM phenylmethylsulfonyl 
                                                  fluoride 
                                                 280mM benzamidine
 
hGdown1 Lysis buffer          50mM Hepes pH7.5                              hGdown1 purification 
                                                 10mM Imidazole 
                                                 300mM NaCl 
                                                 1mM CaCl2 
                                                 10% (V/V) glycerol 
                                                 1 × PI     
                                                 1mM DTT       
 
hGdown1 wash buffer 1      50mM Hepes pH7.5                               hGdown1 purification 
                                                 30mM Imidazole 
                                                 300mM NaCl 
                                                 1mM CaCl2 
                                                 10% (V/V) glycerol 
                                                 1 × PI     




hGdown1 wash buffer 2     50mM Hepes pH7.5                                hGdown1 purification 
                                               50mM Imidazole 
                                               300mM NaCl 
                                               1mM CaCl2 
                                               10% (V/V) glycerol 
                                               1 × PI     
                                               1mM DTT
 
hGdown1 Elution buffer    50mM Hepes pH7.5                                  hGdown1 purification 
                                               30mM Imidazole 
                                               300mM NaCl 
                                               1mM CaCl2 
                                               10% (V/V) glycerol 
                                               1 × PI     
                                               1mM DTT       
 
0M HepR Buffer                  50mM Tris-HCl, pH7.9@4°C                    Pol II purification 
                                               1mM EDTA pH8.0 
                                               10uM ZnCl2 
                                               10% (V/V) glycerol 
                                               1 × PI    
 
0.6M HepR Buffer              0.6M Ammonium sulfate                         Pol II purification 
                                              50mM Tris-HCl, pH7.9@4°C           
                                              1mM EDTA pH8.0 
                                              10uM ZnCl2 
                                              10% (V/V) glycerol 
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                                              1 × PI    
 
0.15M HepR Buffer           0.15M Ammonium sulfate                       Pol II purification 
                                              50mM Tris-HCl, pH7.9@4°C 
                                              1mM EDTA pH8.0 
                                              10uM ZnCl2 
                                              10% (V/V) glycerol 
                                              1mM DTT 
                                              1 × PI    
 
0.2M HepR Buffer            0.2M Ammonium sulfate                           Pol II purification 
                                            50mM Tris-HCl, pH7.9@4°C 
                                            1mM EDTA pH8.0 
                                            10uM ZnCl2 
                                            10% (V/V) glycerol 
                                            1mM DTT 
                                            1 × PI    
 
0.4M HepR Buffer            0.4M Ammonium sulfate                            Pol II purification   
                                            50mM Tris-HCl, pH7.9@4°C 
                                            1mM EDTA pH8.0 
                                            10uM ZnCl2 
                                            10% (V/V) glycerol 
                                            1mM DTT 
                                            1 × PI    
 
0.5M HepR Buffer          0.5M Ammonium sulfate                            Pol II purification   
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                                          50mM Tris-HCl, pH7.9@4°C 
                                          1mM EDTA pH8.0 
                                          10uM ZnCl2 
                                          10% (V/V) glycerol 
                                         1mM DTT 
                                         1 × PI    
 
S-300 Buffer                   5mM Hepes pH7.25@25°C                       Pol II purification   
                                         150mM NaCl 
                                         10uM ZnCl2 
                                         10mM DTT 
                                         1 × PI    
 
Dilution buffer               50mM Tris-HCl pH7.6                                 Pol II purification   
                                         1mM EDTA pH8.0 
                                         10uM ZnCl2 
                                         2mM DTT   
                                         1 × PI    
 
Transcription buffer     20mM Na-Hepes pH7.5                             Transcription assay  
                                         60mM (NH4)2SO4 
                                         8mM MgSO4 
                                         10µM ZnSO4 
                                         10mM DTT 
                                         10% (v/v) glycerol)
 
Stop Buffer                     50mM EDTA                                                Transcription assay 
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                                         6.4M Urea,  
                                         1-fold TBE (Sigma-Aldrich)
 
Template DNA               5'-GATCAAGCTCAAGTACTTAAGCCT             EC formation 
                                         GGTCTATACTAGTACTGCC-3'
 
Non-template DNA       5'-GGCAGTACTAGTATTCTAGTATTG             EC formation      
                                         AAAGTACTTGAGCTTGATC-3'
 
RNA                                 5'-UAUAUGCAUAAAGACCAGGC-3'                EC formation
 
20% denaturing        Urea               8M                 
        Urea gel                       TBE buffer                           1x                
                                              Bis:Acrylamide 19:1  20%  
                                              TEMED   10µL to 10ml 





2.2 Methods  
2.2.1 Expression and purification of human Gdown1 (hGdown1) 
Purification of hGdown1 was performed as described before (Bernecky et al., 2016a). Gene-
optimized hGdown1 (Life Technologies) was cloned into pOPINB (N-terminal His6 tag and 3C 
protease site). The vector was transformed to BL21(DE3)RIL competent cells and plated on 
LB agar plate and cultured overnight in 37°C incubator. Single colony was picked and 
cultured in LB medium with kanamycin and chloramphenicol overnight at 37°C while shaking 
at 160rpm. The overnight E.coli cells were cultured in 2L LB medium (with kanamycin and 
chloramphenicol) at 37°C for 3 to 4 hours till the OD600 arriving to 0.6 to 0.8, then the 
protein was expressed by inducing with 0.5mM IPTG for 3 to 4 hours at 37°C. The cells were 
harvested at a speed of 6000rpm for 15 minutes. The supernatant was gently discarded and 
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the pellet was re-suspended in hGdown1 lysis buffer, frozen in liquid nitrogen, and kept at 
80°C for purification.  
For purification, the re-suspended cells were transferred to a metal beaker for sonication 
with power 20%, 0.6 on, 0.4 off settings for 10 minutes. The sonicated material was 
transferred to 2 centrifugation tubes and spun down for 30 minutes at 4° with Beckman A27 
rotor and a speed of 15,000rpm. The supernatant was transferred to a new tube and filtered 
with 0.8uM filter. The filtered supernatant was loaded to 5ml HisTrap™ High Performance 
column (GE Healthcare) which was pre-equilibrated with hGdown1 lysis buffer. The column 
was washed with 10 CV of hGdown1 lysis buffer, 5CV of hGdown1 wash buffer 1 and eluted 
with 5CV of hGdown1 elution buffer. The eluted protein was mixed with TEV protease (1:10 
ratio of TEV and protein) and dialyzed to hGdown1 lysis buffer overnight. The next day the 
protein was centrifuged at 27,000rpm for 10 minutes to remove the possible precipitation 
after cleavage. The supernatant was loaded to Ni column which was equilibrated with lysis 
buffer beforehand. The flow through was collected, the column was washed with hGdown1 
wash buffer 2 and the washed buffer was also collected. The protein was eluted from Ni 
column and loaded to monoS (GE Healthcare) column. Column was washed for 10CV with 
wash buffer 1 and eluted with a NaCl gradient from 0M to 1M. The peak fractions were 
identified with SDS-PAGE. The target protein was pooled, concentrated and loaded to gel 
filtration. Column Superdex 200 10/300 GL (GE Healthcare) was used for gel filtration. The 
peak fractions were identified again with SDS-PAGE and the target fractions were pooled and 
concentrated to 2 to 3mg/ml with Amicon Ultra-15 Centrifugal Filter Unit (10 kDa MWCO) 
(Merck KGaA, Germany).  The final protein solution was centrifuged at maximum speed for 2 
minutes and aliquoted as 5ul aliquots, frozen in liquid nitrogen and stored at -80°C ready for 
use.  
2.2.2 Purification of Sus scrofa Pol II 
Sus scrofa Pol II was purified essentially as described for the bovine Pol II preparation (Hodo 
and Blatti, 1977; Thompson et al., 1990). 500g frozen pig thymus were crashed into pieces 
with a hammer. The broken pieces were added to a pre-chilled Warning blender with 1L 0M 
HepR buffer and homogenized on high speed for 3 minutes. The homogenized material was 
centrifuged with SLA-1500 rotor at 11,000rpm for 20 minutes at 4°C. Unless special 
emphasis, all the steps below were carried out at 4°C. The supernatant was filtered with 2 
layer of miracloth into a chilled glass graduated cylinder and then transferred to a chilled 2L 
beaker with stirring bar. 5% polyethylenimine (PEI, Sigma-Aldrich) was slowly added to a 
final concentration of 0.02% while stirring. The stirring was kept at 4°C for at least 10 
minutes. Then the precipitated material was transferred to the centrifugation tubes and 
centrifuged with SLA-1500 rotor at 11,000rpm for 20 minutes. The pellet from the 
centrifugation was fully re-suspended with 0.15M HepR buffer and centrifuged with SLA-
1500 rotor at 11,000rpm for 20 minutes. At the same time, the MacroPrep Q column was 
washed with 2 column volume (CV) water, 2CV 0M HepR buffer, 3CV 0.6M HepR buffer and 
equilibrated with 2CV 0.2M HepR buffer. After centrifugation, the supernatant was adjusted 
to the conductivity of 0.2M HepR buffer and loaded to MacroPrep Q column with a very slow 
15 
 
flow rate (gravity flow). After loading, the column was washed with 3CV of 0.2M HepR buffer 
before eluting with 3CV of 0.4M HepR buffer. The eluted fraction was precipitated slowly 
with finely ground ammonium sulfate till saturation while stirring. The stirring was kept for 
at least one hour at 4°C before centrifuging with F14 rotor at 15,000rpm for 30 minutes. 
After centrifugation, the supernatant was gently removed and the pellet was dissolved in 0M 
HepR buffer with 1mM DTT. This was named as ‘Ab input’. The conductivity of ‘Ab input’ was 
adjusted to match the conductivity of 0.15M HepR buffer and followed by a centrifugation at 
15,000rpm for 30 minutes.  The 8WG16 (αRPB1 CTD) antibody-coupled Sepharose column 
was equilibrated with 0.15M HepR buffer and the Ab input was loaded to the antibody 
column in gravity flow (the beads bed was not allowed to be disturbed during the whole 
process). The column was washed with 0.5M HepR buffer (also in gravity flow) and then 
moved to room temperature. The antibody column was kept at room temperature for at 
least 15 minutes to make sure the resin is at room temperature. Then the protein was eluted 
with 0.5M HepR buffer plus 50% (v/v) glycerol. The eluted drops were collected with 50ml 
conical tubes containing 20ml dilution buffer. The elution was fractionated every 5ml, in 
total 5 fractions were collected. After elution, all the fractions were identified with SDS-
PAGE. Fractions with Pol II were collected and loaded to UnoQ column (Biorad) which was 
equilibrated with 0.1M HepR buffer beforehand. UnoQ column was washed with 5CV of 
0.1M HepR buffer and eluted with a linear gradient from 0.1M HepR to 0.5M HepR. The peak 
fractions were taken and loaded to SDS-PAGE gel. Fractions without pig Gdown1 were 
pooled, 3-fold molar excess of hGdown1 was added and kept on ice for 2 to 3 hours. Then 
the sample was loaded to a HiPrep 16/60 Sephacryl S-300 HR column (GE Healthcare, Little 
Chalfont, United Kingdom). Peak fractions were identified with SDS-PAGE and fractions 
containing the Pol II-hGdown1 complex were collected and concentrated to a concentration 
of 2-3 mg/ml using an Amicon Ultra-15 Centrifugal Filter Unit (100 kDa MWCO) (Merck 
KGaA, Germany). Sample aliquots were snap frozen in liquid nitrogen and stored at -80 °C 
prior to use. The typical yield is about 2-4 mg from ~500 g pig thymus. 
2.2.3 SDS-PAGE 
SDS-PAGE was performed by using pre-cast NuPAGE Bis-Tris 4-12% gels (Invitrogen). 4x 
NuPAGE LDS loading buffer (Invitrogen) was added to the Protein sample to a final 
concentration of 1x. The samples were boiled at 95°C for 5 to 10 minutes and loaded 
carefully to the wells of the gel. At least one well of one gel should be loaded with protein 
marker (precision plus proteinTM Dual Color Standards, BIO-RAD). Gels were run in either 
1xMES or 1xMOPS buffer (diluted from NuPAGE 20 x stock, Invitrogen. For small proteins, 
MOPS buffer has better resolution) for 30 to 60 minutes at 200V. After running, gels were 
taken out and stained with InstantBlue (Expedeon). The destaining of the gels was 
performed with water and the gel was scanned with Epson Perfection V700 Photo 
Fachbettscanner. 
2.2.4 Formation of elongation complex (EC) 
 The DNA scaffold used for the EC is the same as the one used for the bovine RNA 
polymerase II-DSIF complex (Bernecky et al., 2016a). A 20nt RNA was used for the formation 
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of a 9nt DNA-RNA hybrid and 11nt of exiting RNA. The template DNA/RNA was annealed 
(Brueckner et al., 2007) and a 1.5 fold molar excess of scaffold was added to the Pol II-
hGdown1 complex. The sample was incubated on ice for 10 min and subsequently incubated 
for an additional 15 min at 20 °C while shaking at 550rpm. Then the non-template DNA was 
added and the sample was kept at 20°C for another 20 minutes. The complex was 
crosslinked with 3mM BS3 (Thermo Scientific, final concentration) on ice for 30 min. The 
crosslinking reaction was quenched with 50mM ammonium bicarbonate and applied to a 
Superdex 200 increase 10/300 GL column (GE Healthcare) pre-equilibrated with S-300 
buffer. The peak containing the complex was pooled and concentrated to a concentration of 
473 µM. A 1.5-fold molar excess of α-amanitin was added to the elongation complex. The 
sample was incubated on ice for 20 min and then loaded directly to the grids. 
2.2.5 Electron microscopy  
4 µL of the protein complex solution was applied to glow-discharged Quantifoil R2/2 gold 
grids (Quantifoil) and plunged into liquid ethane after blotting with a FEI Vitrobot Mark IV 
(FEI, Hillsboro, USA). Images were acquired on a FEI Titan Krios, operated at 300 keV and 
equipped with a Gatan K2 Summit direct electron detector and a Quantum GIF. Micrographs 
were collected automatically with the software package EPU (FEI) at a nominal magnification 
of 130k (1.07 Å per pixel) in counting mode. The dose rate was 3.8 e-/pixel/s. Three images 
were acquired per foil hole. Each micrograph was collected with a total dose of 35 electrons 
per square angstrom over a 10-second exposure, fractionated into 40 frames (0.25 s each). 
Defocus values ranged from −1 to −3 µm. Micrograph frames were aligned and corrected 
with MmotionCcorr2 (Zheng et al., 2017). Unless otherwise noted, data processing was 
performed using RELION 2.1 (Fernandez-Leiro and Scheres, 2017). Contrast transfer function 
(CTF) parameters were estimated using Gctf (Zhang, 2016). Initial 2D classes were calculated 
from 2,909 manually selected particles from 37 micrographs. The initial 2D classes were used 
as templates for auto-picking. After manual inspection of all 2,049 micrographs, a total of 
207,410 particles were obtained.  Two rounds of 2D classification were performed and bad 
particles were removed.  The resulting data set of 134,512 particles was used for further 
refinement and focused classification refinement in 3D. The Bos taurus Pol II structure 
(EMDB accession code EMD-3219) (Bernecky et al., 2016a) was low-pass filtered to 40 Å as 
an initial model for 3D refinement. Initial 3D refinement followed by movie processing and 
particle polishing yielded a reconstruction at an overall resolution of 3.4 Å (gold-standard 
Fourier shell correlation criterion 0.143, RELION 2.1). Focused 3D classification without 
image alignment was performed on the α-amanitin binding pocket, the Pol II stalk (RPB4-
RPB7) and upstream DNA, followed by global 3D refinement. 
2.2.6 Model building and refinement 
Model building was based on the previously published bovine Pol II structure (PDB accession 
code 5FLM)(Bernecky et al., 2016a). The model was manually fitted in COOT (Emsley et al., 
2010). The α-amanitin molecule was taken from a Saccharomyces cerevisiae α-amanitin-
bound Pol II structure (PDB accession code 2VUM)(Brueckner and Cramer, 2008). The α-
amanitin molecule was rigid body fitted into the density. The structure was refined in real 
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space with special restraints to the nucleic acids and α-amanitin using PHENIX (Torices and 
Muñoz-Pajares, 2015). 
2.2.7 Transcription assay  
Template DNA and RNA were mixed at a molar ratio of 1:1 and annealed as described 
(Brueckner et al., 2007). The template annealed DNA-RNA was mixed with Pol II-hGdown1 
complex at a molar ratio of 1:2 and incubated at 28 ℃ for 10 min. Non-template DNA was 
added and incubated at 28 ℃ for an additional 10 min. The elongation complex was mixed 
with α-amanitin or buffer (control) at the same molar ratio used for the complex formation. 
The sample was subsequently incubated on ice for 20 min. 100 μM UTP was added to both 
control and experimental reactions. The reaction was incubated in transcription buffer at 28 
℃ and samples were taken at indicated time points. The reaction was stopped by adding 
stop buffer to the reaction. The product RNA was separated using a 20% denaturing urea 
polyacrylamide gel (300V) and visualized using a GE Typhoon FLA 9500 (GE Healthcare). 
3 Results 
3.1 Purification of Sus scrofa Pol II 
Sus scrofa Pol II was purified essentially as described for the bovine Pol II preparation, except 
that pig thymus instead of bovine thymus was used (Method). Briefly, thymus was 
homogenized, and the supernatant was filtered. After polyethyleneimine precipitation, Pol II 
was purified with a MacroPrepQ column, followed by ammonium sulfate precipitation and 
an affinity column with 8WG16 (αRPB1 CTD) antibody-coupled Sepharose, a UnoQ anion 
exchange column, and finally a Sephacryl S-300 HiLoad sizing column (Figure 1.3). The typical 
yield was 2~4 mg from ∼500 g of thymus. The fractions from UnoQ column were strictly 
selected to avoid pig Gdown1 contamination, then hGdown1 which was expressed and 
purified from E.coli was combined with Pol II and purified by gel filtration. Incubation of Pol II 




Figure 1.3: Purification of Sus. Scrofa Pol II from pig thymus and formation of Pol II-
hGdown1 complex. A, chromatogram of UnoQ column, Pol II was concentrated by UnoQ 
with a high peak coming out within the elution gradient. B, SDS-PAGE of UnoQ fractions, the 
volume increases from left to right, the earlier Pol II fractions including pig Gdown1 were 
trashed. C, chromatogram of HiPrep Sephacryl S-300 column. The volume of the column is 
120ml. Pol II comes out around 50ml. D, SDS-PAGE of the gel filtration fractions. hGdown1 
was bound to Pol II stably after incubation. 
3.2 Pol II elongation complex formation, assay of activity inhibition by 
α-amanitin and cryo-EM grids preparation 
The EC was formed with a DNA-RNA scaffold that was highly similar to a previously used one 
(Bernecky et al., 2016a). The EC was active in RNA synthesis and was inhibited after α-
amanitin addition (Figure 1.4B). The EC sample was cross-linked with BS3, incubated with α-
amanitin, and immediately applied to EM grids before flash freezing. Cryo-EM analysis 
revealed a homogeneous distribution of particles that could be classified easily (Figure 1.4C). 
134,512 particle images were extracted with RELION and used for 3D reconstruction, 




Figure 1.4: Pol II elongation complex (EC) formation, in vitro RNA extension assay, and 
exemplary micrograph and 2D classes of the dataset. A, SDS-PAGE analysis of the Pol II-
hGdown1 complex. B, the reconstituted Pol II-hGdown1 EC is active in RNA extension and 
inhibited by α-amanitin. In the absence of α-amanitin (upper panel), two uridine residues 
were incorporated into the RNA of the scaffold upon incubation with 100mM UTP, as 
expected from the presence of two templating adenine bases downstream. In the presence 
of α-amanitin (lower panel), nucleotide addition is slowed down, and addition of only one 
uridine residue was observed, as expected from impaired Pol II translocation. C, 
representative micrographs and 2D classes generated from the cryo-EM data set. 
 
3.3 Pol II EC-hGdown1-α-amanitin complex data processing 
Particles were extracted from micrographs with RELION. Three rounds of 2D classification 
were executed to sort out the bad particles. Good particles were saved for further data 
processing. Bovine Pol II (EMD-3219) was filtered to 40 Å as an initial model for 3D 
refinement and 3D classification. Focus classifications and refinements were used for 
upstream DNA, α-amanitin pocket and RPB4/7 respectively to improve the model (Figure 
1.5). Local resolution was measured along with angular distribution. The resolution of the α-
amanitin pocket was about 3 Å (Figure 1.6), which was higher than the overall resolution 




Figure 1.5: Cryo-EM data processing. The structure of bovine Pol II (EMD-3219) was low-
pass filtered to 40 Å and used as the initial reference model. Semi-automatically picked 
particles were used for 3D refinement. Data processing with 3D refinement, movie 
processing and particle polishing gave a final reconstruction at a nominal resolution of 3.4 Å. 
Focused classifications and refinements were performed on upstream DNA, α-amanitin and 




Figure 1.6: Local resolution of the cryo-EM density map. A, Three views of a surface 
representation of the final cryo-EM density map colored according to local resolution. B, The 
same views as in ‘A’ but sliced open to reveal the very high resolution at the active center of 
the polymerase and around the α-amanitin binding pocket. C, FSC plots for the cryo-EM 
reconstruction and for the model versus the cryo-EM reconstruction. D, angular distribution 
map of single particle images. Black shading indicates the number of particles assigned to a 
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given view, while red dots indicate represented views. E, Resolution versus number of 
particles plot using random particle subsets with logarithmic and squared reciprocal axes. 
The slope of the linear fit indicates an overall B-factor of 101 Å2. 
3.4 Overall structure analysis of mammalian Pol II EC-α-amanitin 
complex and comparison with yeast EC-α-amanitin complex 
To obtain an atomic model of the mammalian Pol II EC α-amanitin complex, we placed the 
previously refined bovine Pol II structure into the density and adjusted it locally (Bernecky et 
al., 2016a). There was no density for hGdown1, which apparently dissociated from the 
complex. The region around the Pol II active center, including α-amanitin and its binding 
pocket, was well resolved, with an estimated local resolution of 3.0 Å (Figure 1.6). There 
were no other significant additional densities observed. We could build an atomic model for 
α-amanitin and define its chemical interactions with Pol II (Figure 1.8 and Table 1.2). The 
structure was finished by manual adjustments and real-space refinement. The structure of 
the Pol II EC is highly similar to the previously determined structure of the bovine 
counterpart (Bernecky et al., 2016a). 
Pig Pol II differs from bovine Pol II in only five residues: RPB1 Glu1968, RPB5 Glu32 and 
Asp46, RPB6 Ser126, and RPB9 Phe11. The EC adopts the post-translocation state with a 
straight bridge helix, different from the slightly bent bridge helix observed in the yeast Pol II- 
α-amanitin crystal structure, which is thought to reflect a translocation intermediate 
(Brueckner and Cramer, 2008). The trigger loop adopts a conformation that most closely 
resembles the ‘wedged’ conformation previously observed in the yeast EC bound by α-
amanitin (Brueckner and Cramer, 2008). However, residue Leu1104 (Leu1081 in yeast), 
which forms a wedge behind the bridge helix in the yeast structure (Brueckner and Cramer, 
2008), protrudes 2 Å less in between the bridge helix and the polymerase cleft module, 
essentially not forming a wedge anymore, and consistent with the observed straight bridge 
helix. We refer to this slightly altered trigger loop conformation as ‘unwedged’ because it is 





Figure 1.7: Cryo-EM structure of mammalian Pol II EC bound by α-amanitin. A, nucleic acid 
scaffold is depicted schematically. Filled and unfilled circles represent modeled and not 
modeled nucleotides, respectively. The nucleotide-binding site (red dashed circle), bridge 
helix (green), the catalytic metal ion A (pink), trigger loop (brown), and α-amanitin (orange) 
are indicated. The color code is used throughout. B, Overview of the structure. Pol II is 
shown as a silver ribbon model, and other elements are colored as in A. C, electron density 
for α-amanitin (orange mesh) in three different views. Important contact moieties with Pol II 
are indicated. Nitrogen, oxygen, and sulfur atoms are blue, red, and yellow, respectively. 
3.5 Specificity of α-amanitin binding pocket in mammalian 
The position and binding pocket of α-amanitin is as observed in the yeast EC (Figure 1.7) 
(Brueckner and Cramer, 2008). Most contacts between α-amanitin and yeast Pol II observed 
in the EC are conserved in the mammalian complex, as expected by the high conservation of 
residues involved in binding the toxin (Figure 1.8). Conserved contacts are also formed by 
His1108 (yeast His1085) in the trigger loop of Pol II. 
Three differences in α-amanitin-Pol II contacts are observed. First, the side chain of RPB1 
residue Ser782, conserved over mammals and other metazoan species, forms an additional 
hydrogen bond with the hydroxyl group in the indole ring of the tryptophan in α-amanitin 
(Figure 1.3; figure 1.4A). Ser782 lines the bottom of a cage, formed by the universally 
conserved Pol II residues Arg749, Ile779, and Gln783, for the indole ring of α-amanitin 
(Figure 1.8, A and B). The yeast residue corresponding to mammalian Ser782 is Ala759 and 
cannot form this hydrogen bond. Second, Asn792 forms an additional hydrogen bond with 
24 
 
its side chain to the backbone carbonyl group of 4,5-dihydroxyisoleucine in α-amanitin 
(Figure 1.8B, C; Figure1.9). This contact is not present in the yeast Pol II-α-amanitin complex, 
because the yeast counterpart of mammalian Asn792 is Ser769, and the observed hydrogen 
bond is thus not possible. There is a third residue in the amanitin-binding pocket that differs, 
Asn742 (Figure 1.8, A and B; Figure1.9), which corresponds to Val719 in yeast, but this is 
unlikely to contribute strongly to the difference in affinity because in both structures these 
residues form van der Waals contacts with the side chain of isoleucine in α-amanitin. 
Thus, compared with the yeast structure, two additional hydrogen bonds are formed 
between α-amanitin and the mammalian EC. It is known that two additional hydrogen bonds 
can give rise to enthalpy changes that account for changes in dissociation constants by 3 
orders of magnitude (Hubbard and Kamran Haider, 2001; Klebe, 2015).We therefore suggest 
that the two additional hydrogen bonds account for the much higher affinity of mammalian 
Pol II for the toxin. This interpretation is supported by known biochemical data obtained 
with amanitin derivatives that lack certain functional groups (Baumann et al., 2008; 
Kinghorn, 1987). In particular, alkylation of the hydroxyl group in the indole ring is predicted 
to prevent hydrogen bond formation and is known to decrease toxicity and inhibitory 
potential of amanitin (Kinghorn, 1987). 
 
Figure 1.8: Interaction analysis of mammalian Pol II with α-amanitin. A, sequence 
alignment of residues forming the α-amanitin-binding pocket in RPB1 between various 
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metazoan species and the yeast S.cerevisiae (bottom row). The red boxes indicate amino 
acid residues that form metazoan-specific interactions with α-amanitin. Helices α21 to α24, 
bridge helix, and trigger loop are indicated at the bottom of the sequence alignment. B, 
schematic overview of Pol II-α-amanitin interactions. The chemical structure of α-amanitin is 
shown in orange. RPB1 residues conserved over eukaryotes are labeled in black, whereas 
metazoan-specific α-amanitin-interacting residues are labeled in red. The green dashed lines 
indicate hydrogen bonds, whereas black dashed lines show other interactions. C, surface 
representation of the amanitin-binding Pol II pocket. Positively and negatively charged 
surfaces are in blue and red, respectively. The bridge helix, trigger loop, and RPB1 residue 
Ser782 are indicated. 
 
Table 1.2: Hydrogen bonds between α-amanitin and S. scrofa Pol II 
 
3.6 α-amanitin resistance caused by binding pocket mutations 
The structure also suggests the molecular basis for α -amanitin resistance arising from 
mutations in the binding pocket in Pol II enzymes from mice (Bartolomei and Corden, 1987; 
Bartolomei and Corden, 1995) and Drosophila (Chen et al., 1993). Modeling shows that 
mutation I779F in mouse RPB1 leads to a steric clash that likely prevents α-amanitin from 
binding (Figure 1.9B). The additional mouse mutations L745P and R749P likely destabilize 
helix 21, which forms part of the binding pocket (Figure 1.9B). The Drosophila melanogaster 
Rpb1 mutations N792D and N793D are predicted to disrupt hydrogen bonds between Pol II 






Figure 1.9: Extra hydrogen bonds in mammalian and binding pocket mutation analysis. A, 
two metazoan-specific hydrogen bonds are indicated with green dashed lines, and the  
corresponding bond lengths are indicated between α-amanitin and mammalian RPB1. B, 
modeling of site-specific mutations in the α-amanitin binding pocket that confer resistance 
to α-amanitin in Mus musculus. The Pol II model is shown with gray sticks, whereas the 
mutated amino acids are shown with magenta sticks. 
 4. Discussion 
In the structure, no density was shown for hGdown1, it might fall off during elongation 
complex formation or during freezing. However, we need it to make Pol II more 
homogeneous. Because from the previous experience, even the same fraction from the 
same gel filtration peak showed a mixture of pol II monomer and dimer, which made the EM 
processing difficult. However, with hGdown1 binding, the dimer almost disappears and Pol II 
dimer shows very homogeneous distribution on the grids. The reason is not clear so far, 
which might need a further study in the future. 
More than one century after the discovery of α-amanitin (Ford, 1907), we now provide an 
atomic model of its structure in complex with its natural target, the mammalian Pol II EC. 
This work provides the structural basis of mammalian Pol II inhibition by α-amanitin. 
Whereas insights into the mechanism of transcription inhibition by α-amanitin were already 
derived from structures of the yeast Pol II (Bushnell et al., 2002) and the yeast EC (Brueckner 
and Cramer, 2008), our current work additionally provides a molecular explanation for the 
long-standing observation that α-amanitin has a much higher affinity for mammalian Pol II, 
compared with the yeast enzyme. Most notably, we observe two additional, well defined 
hydrogen bonds that are possible in mammalian Pol II enzymes, but not in yeast Pol II, 
explaining the tighter binding of the toxin to the former. Together with recent studies (Gao 
et al., 2016; Wong et al., 2017), our work also shows that cryo-EM can now be used to study 
the detailed interactions of small molecules with proteins, as required for drug design. We 
note that such applications of cryo-EM still often require that the target molecule or 
complex has a critical size. In the future, further developments of cryo-EM will, however, 
likely remove this limitation such that the inhibition of target molecules and complexes of 













1.1 transcription termination 
As introduced in chapter1, transcription starts with the recognition of promoter sequences 
by initiation factors, then both RNAP and initiation factors bind to the promoter and initiate 
the transcription. In eukaryotes, the transcription of Pol II would suffer from a promoter- 
proximal pausing before releasing to the gene body (Rougvie and Lis, 1990). The RNAP, 
stimulated by elongation factors, walks along double strand DNA and produces RNA. When 
elongation complex encounters termination signals encoded in the DNA sequence, 
transcription terminates to avoid interfering with the neighboring transcriptional units and 
to promote RNAP recycling (Kuehner et al., 2011; Richard and Manley, 2009).  
Transcription termination means that both RNAP and the transcript dissociate from the 
template DNA and the transcription of current unit is finished (Porrua et al., 2016; Porrua 
and Libri, 2015). There are two main reasons for keeping the processivity of the elongation: 
the interactions between RNAP, elongation factors and nucleotides (Kuehner et al., 2011), 
and the DNA:RNA hybrid which is 8 nucleotides in length and is maintained during the 
elongation process (Kireeva et al., 2000; Komissarova et al., 2002). So to dismantle the 
elongation complex, there are two main processes. Firstly, the abolishment of the 
interactions between RNAP and elongation factors, which means termination/3' processing 
factors bind to RNAP or RNA and replace the elongation factors (Mandel et al., 2008). The 
second important process is the separation of the 8nt DNA:RNA hybrid which stabilizes the 
elongation complex. Thus, a helicase is necessary to open the DNA:RNA hybrid and cause the 
collapse of the elongation complex (Porrua and Libri, 2013).  
Mechanism of transcription termination is different in different organisms and also varies 
between Pol I, Pol II and Pol III. A short introduction follows for transcription termination in 
bacterial, Pol I and Pol III and Pol II respectively. 
1.1.1 Transcription termination in bacterial   
In bacteria, there are two different termination pathways depending on whether it is factor 
dependent or it relies only on the signal in the template DNA. The later was named intrinsic 
termination while the former was named Rho-dependent termination, as the factor Rho is 
necessary in this pathway (reviewed in Roberts, 2019).  
For intrinsic termination, the signal in the template DNA or the product RNA is important 
and consists of a GC rich hairpin followed by a run of U (d'Aubenton Carafa et al., 1990). In 
the early termination process, RNAP pauses and an unstable DNA:RNA hybrid is formed. At 
the same time, the 'U' sequence is synthesized (Gusarov and Nudler, 1999). The synthesis 
process provides enough time for the formation of the hairpin, which might have several 
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roles in the termination process (Roberts, 2019). Firstly, the hairpin might initiate the 
dissociation of the DNA:RNA hybrid with the help of the U tract. Secondly, the hairpin might 
help to push the bacterial RNAP forward without nucleotide addition, which ends up with 
the release of RNA and RNAP, and the dissociation of the DNA:RNA hybrid (Gusarov and 
Nudler, 1999). The third hypothesis is that the formation of the hairpin causes a 
conformational change in RNAP, which might result in the destabilization of the elongation 
complex and transcription termination (Lang et al., 1998). This is the allosteric model 
(Epshtein et al., 2010). While the key point for the first two models is the dissociation of 
DNA:RNA hybrid, the central idea for the third model is the conformational change in RNAP. 
In Rho-dependent pathway, the factor Rho is strictly necessary for termination (Banerjee et 
al., 2006). Rho is a ring-shaped, homo-hexameric complex, which has RNA binding, 
translocase and ATP hydrolysis activities. The active form of Rho is an open ring which allows 
RNA binding to the center of the ring (Roberts, 1969). The RNA binding site is featured by C 
rich and G poor sequences. Once bound to RNA, the Rho motor translocates towards the 3' 
end and ultimately catches up with RNAP to dislodge it from DNA (Kuehner et al., 2011). 
Termination in eukaryotes is different but also shows conservations with bacteria, for 
example, the dissociation of DNA:RNA hybrid is important for termination in both bacteria 
and eukaryotes (Komissarova et al., 2002), which would be introduced as follows. 
1.1.2 Transcription termination of Pol I and Pol III  
Pol I transcribes the ribosomal RNAs (rRNAs) and Pol III transcribes non-coding RNAs, such as 
tRNAs, U6 spliceosomal snRNAs etc. For Pol I termination in mammals, the termination 
signal 'Sal box' is important to stop the elongation and release the RNA chain. The featured 
sequence for 'Sal box' is AGGTCGACCAGA/TT/ ANTCCG in mouse (Grummt et al., 1985; Kuhn 
et al., 1988). ‘Sal box’ is recognized by transcription termination factor for Pol I (TTF-1) 
(Bartsch et al., 1988; Evers et al., 1995). Termination occurs 11bp upstream of 'Sal box' with 
the help of Pol I and transcript release factor (PTRF)(Mason et al., 1997). Rnt1 is the RNA 
cleavage factor (Kufel et al., 1999). Some studies showed that Pol I might have similar 
termination mechanisms like Pol II, such as the torpedo model (Kawauchi et al., 2008). 
However the detailed mechanism for Pol I termination is not well understood so far. 
Pol III can terminate transcription by itself. C11 is one of the subunits of Pol III which 
mediates the cleavage activity and re-initiation (Whitehall et al., 1994). Subunits C37/C53 
can reduce the elongation rate of Pol III after termination signal and lead to release of Pol III 
and transcripts (Landrieux et al., 2006). The most obvious termination signal is the T stretch 
40bp downstream of the mature 3' end of RNAs. Sequences surrounding T tract can also 
affect the termination efficiency (Cozzarelli et al., 1983). 
1.1.3 Transcription termination of Pol II 
As mentioned before, Pol II transcribes not only protein coding genes (mRNAs) but also non-
coding RNAs (ncRNAs). There are different pathways for mRNAs and ncRNAs termination in 
yeast and humans, as follows. 
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1.1.3.1 Pol II termination pathways in yeast 
Transcription termination is well studied in yeast. Based on different types of termination 
factors and product RNAs, there are two different pathways for Pol II termination (Kim et al., 
2006): the sen1-dependent pathway (Creamer et al., 2011; Jamonnak et al., 2011), which is 
normally for ncRNAs, and the Poly(A) dependent pathway, which is for mRNAs (Logan et al., 
1987; Whitelaw and Proudfoot, 1986).  
The main step in the sen1 dependent pathway is the separation of the DNA:RNA hybrid as 
discussed before (Steinmetz and Brow, 1996). The hypothesis is that sen1 works as a 
helicase and unwinds the DNA:RNA hybrid with the help of RNA binding factors, Nrd1 and 
Nab1 (Arigo et al., 2006; Thiebaut et al., 2006). These three factors comprise the Nrd1-Nab1-
Sen1 (NNS) complex which works on ncRNA termination, the pathway is also named as NNS 
pathway. The disruption of DNA:RNA hybrid by sen1 is ATP-dependent and causes the 
dissociation of the whole elongation complex and results in Pol II and RNA release from the 
template DNA (Porrua et al., 2012)(Figure 2.1B).  
Poly(A) dependent pathway is a bit more complex, because poly(A) dependent termination 
is coupled by the pre-mRNA 3’ processing and more protein factors, along with sequence 
elements on pre-mRNA are involved (Edwalds-Gilbert et al., 1993; Plant et al., 2005). The 
yeast poly(A) signal is composed of at least three cis elements: the AU-rich efficiency 
elements (EE) (Guo et al., 1995; Irniger and Braus, 1994; Zhao et al., 1999), the A rich 
positioning elements (PE)(Guo and Sherman, 1995, 1996) and the U-rich elements located 
upstream (UUE) or downstream (DUE) of the cleavage site (Heidmann et al., 1994). The 
cleavage site is featured by a pyrimidine followed by multiple adenosines Y(A)n and the 
cleavage occurs at the 3’ end of one adenosine (Heidmann et al., 1992; Heidmann et al., 
1994). Poly(A) signal is recognized by termination complexes which include cleavage and 
polyadenylation factor (CPF), cleavage factor 1A and 1B (CFIA and CFIB). Ysh1 is one of the 
subunits of the CPF complex and it is responsible for the cleavage of pre-mRNA (Garas et al., 
2008). The cleavage of pre-mRNA splits the molecule into two pieces, one composed of the 
3' end and the other of the 5' end of the pre-mRNA. The 3' end RNA is the target ‘mRNA’, 
which is polyadenylated at the 3’ end by the polymerase of polyadenylation 1 (Pap1), with 
the help of 3’ processing factors (Ezeokonkwo et al., 2012). After 3’ polyadenylation, the 
mature mRNA is transported to cytoplasm for translation. Unlike the 3’ end of the pre-
mRNA, the 5' end is still associated with the paused elongation complex, the 5’ end is 
degraded by Rat 1 exonuclease, which forms a complex with Rail1 and Rtt103 (Kim et al., 
2004b; Xiang et al., 2009). There are two main models describing how Pol II is released from 
template DNA: allosteric model and torpedo model (Richard and Manley, 2009) (Luo et al., 
2006). The hypothesis for allosteric model is that the cleavage of the pre-mRNA and binding 
of termination factors cause a conformational change in the elongation complex, which ends 
with the release of Pol II, elongation factors and RNA from the template DNA (Kim et al., 
2004a; Zhang et al., 2005). For torpedo model, the exonuclease Rat 1 is the main factor (Kim 
et al., 2004b). The hypothesis is that after the pre-mRNA cleavage, the exposed 5' end of the 
pre-mRNA is degraded by Rat1 assisted by Rail1 and Rtt103 (Dengl and Cramer, 2009; 
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Pearson and Moore, 2013). The exonuclease ‘chews’ along the RNA until it collides with Pol 
II. The collision causes the collapse of the elongation complex and releases of Pol II from 
template DNA (Figure 2.1A). However, it is still under debate if the collision can generate 
enough force to cause the termination (Dengl and Cramer, 2009). Moreover, it may be that a 
combination of the two models holds true and the termination occurs with both 
conformational change of the elongation complex and the collision of Rat1 with Pol II (Luo et 
al., 2006). 
 
Figure 2.1: Transcription termination pathways in yeast. A, CPF-CF pathway is used for the 
termination of protein coding genes, in which CPF-CF complex, along with some other 
termination factors is recruited to Ser2 phosphorylated CTD. After pre-mRNA is cleaved at 
the cleavage site by Ysh1, there are two hypothetical models for how Pol II is released from 
template DNA, torpedo model and allosteric model. B, termination of noncoding RNAs is 
executed by Nrd-Nab3-Sen1 (NNS) pathway, the dissociation of DNA:RNA hybrid by Sen1 
causes dissociation of elongation complex. Diagram was adapted from Jason N. Kuehner et 
al., MCB, 2011 
1.1.3.2 Termination pathways in metazoans 
Transcription termination in mammalian Pol II is similar to its yeast counterpart but with 
some differences. For example, the NNS termination pathway for ncRNAs is not conserved in 
human, as senataxin (SETX), the inferred homologue of sen1 in human, shows different 
function (Moreira et al., 2004). However, another pathway executed by integrator complex 
and ARS2 was well studied in snRNA termination, which needs the function of NELF (Gruber 
et al., 2012; Hallais et al., 2013; Narita et al., 2007)(Figure 2.2B). There is no helicase in the 
complex and the termination occurs by the exchange of elongation factors to termination 
factors. However, the detailed mechanism of this pathway has not yet been described.  
Termination for pre-mRNAs is similar to its yeast counterpart, but there are more factors 
participating and the sequence elements on pre-mRNA are more conserved. There are more 
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than 20 protein factors participating in 3' processing in human cells (Mandel et al., 2008; 
Xiang et al., 2014). Depending on the functional differences, they are divided into different 
complexes, which includes cleavage and polyadenylation specificity factor (CPSF), cleavage 
stimulation factor (CstF), cleavage factor I and II (CFI and CFII), Symplekin (SYMPK) and 
polymerase for polyadenylation (PAP)(Christofori and Keller, 1988; Gilmartin and Nevins, 
1989; Takagaki et al., 1989). There are several cis elements on the pre-mRNA recognized by 
the 3' processing factors. Firstly, the highly conserved polyadenylation signal (PAS), featuring 
AAUAAA, is normally 10 to 35 nucleotides upstream of the cleavage site (Beaudoing et al., 
2000; Hu et al., 2005; Pauws et al., 2001). PAS site is specifically recognized and bound by 
CPSF complex. Secondly, the downstream elements (DSE) featuring GU/U rich sequence, is 
30 nucleotides downstream of the cleavage site and bound by CstF complex (Chou et al., 
1994; Gil and Proudfoot, 1987; McLauchlan et al., 1985). DSE is not as conserved as PAS site 
and varies in different genes (McLauchlan et al., 1985). Thirdly, the upstream element (USE), 
which is composed of multiple UGUA motifs and is positioned 40 to 100 nucleotides 
upstream of the cleavage site. USE is bound specifically by CFI complex (Hu et al., 2005). The 
cleavage site is featured by 'CA' and cleavage normally occurs between 'C' and 'A' (Chen et 
al., 1995).  
The allosteric model and torpedo model were also widely accepted in the termination of 
mammalian protein coding genes (Figure 2.2A). The overall idea is similar as in yeast. In 
torpedo model, the cleavage of pre-mRNA is executed by CPSF73, the homologue of Ysh1 
(Mandel et al., 2006). Afterwards, the mature mRNA is exported to the cytoplasm for 
translation. At the same time, the 5’end RNA was degraded by XRN2, which is the 
exonuclease in human (homolog of Rat1)(West et al., 2004). SETX functions in promoting 
XRN2-dependent termination (Skourti-Stathaki et al., 2011)(Figure 2.2A). 
 
Figure 2.2: Transcription termination in metazoans. A, Poly(A) dependent pathway in 
protein coding genes in metazoans. 70% of mammalian genes have the highly conserved 
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AAUAAA site, which is recognized by CPSF complex associated with other factors. The 
torpedo model and allosteric model also exist in metazoans and are highly conserved in 
yeast and human. B, termination in noncoding RNAs in metazoans is different than in yeast. 
NNS pathway has not been discovered in mammals so far. Instead, ARS2 and integrator 
complex execute the termination of noncoding RNAs in mammals. The diagram was adapted 
from from Jason N. Kuehner et al., MCB, 2011 
1.2 3' end processing 
The polyadenylation at the 3’ end occurs in most of the protein coding RNAs, as the poly(A) 
tail is required for mRNA maturing. However, the histone mRNA is an exception, the pre-
mRNA of histones is cleaved after a stem-loop structure and the upstream RNA is not 
polyadenylated (Dominski et al., 2005; Marzluff et al., 2008). For the other protein coding 
genes, a poly(A) tail is added to the 3' end by the PAP (Wahle, 1991). In mammals, the length 
of the poly(A) tail is normally ~250 nt. The length of poly(A) tail is determined by a crosstalk 
between PABPN1, CPSF and PAP (Kuhn et al., 2009; Wahle, 1995). There are several 
functions of poly(A) tail, which includes the  protection of mRNA from degradation, 
localization of mature  RNA in the cells, transportation of mRNA from nucleus to cytoplasm 
and the translation efficiency (Preiss and Hentze, 1998). 
After the RNA cleavage, the PAP adds the 250nt poly(A) tail to the 3' mRNA by using ATP 
(Balbo and Bohm, 2007; Martin et al., 2000). In metazoans, there are at least four different 
PAPs, including PAP, Neo-PAP, star-PAP and TPAP (Chan et al., 2011; Edmonds, 1990). The 
canonical PAP is the most well studied one and it is conserved between yeast and human 
(Raabe et al., 1991; Wahle, 1991). PAP belongs to the DNA polymerase ß family and the 
structure study reveals a three-globular-domain organization (Edmonds, 1990). The active 
site hides between the three domains and opens upon substrate binding (Balbo et al., 2007; 
Bard et al., 2000; Martin et al., 2004). The C terminal extension of PAP exists only in higher 
eukaryotes and is enriched with serine and threonine (Martin and Keller, 1996). The serine 
and threonine region is the target for posttranslational modifications, which is related with 
PAP activity modulation (Zhao and Manley, 1996). In 3' processing, PAP was shown to 
associate with CPSF complex for its function (Takagaki et al., 1990). 
1.3 Termination/3' end processing factors in human 
In human cells, transcription termination and pre-mRNA 3' end processing are two different 
processes. However, termination is normally coupled by the pre-mRNA 3' end processing 
and they share the necessary protein factors (Bentley, 2005). Comparing with co-
transcriptional capping and splicing, which occur at the beginning and in the middle of the 
transcription cycle, respectively, 3' end processing normally happens at the end of 
transcription and is coupled with termination (Bentley, 2014). There is a big machinery which 
is responsible for termination and 3' end processing. According to early biochemistry 
identification, these factors can be grouped into four sub-complexes: CPSF complex, CstF 
complex, CFI and CFII (Takagaki et al., 1989) and single subunit PAP. A short introduction 




In human, CPSF complex is composed of at least 6 subunits, which include CPSF160, CPSF30, 
WDR33 (Shi et al., 2009), Fip1 (Kaufmann et al., 2004), CPSF100 and CPSF73 (Murthy and 
Manley, 1992; Wahle, 1991). CPSF160 is the scaffold protein and is composed of tandem 
WD40 repeats clustered into three major ß-propellers (Neuwald and Poleksic, 2000). Based 
on the functional differences, CPSF complex is divided into two modules, the polymerase 
module (CPSF160, CPSF30, WDR33, Fip1) (Clerici et al., 2017; Clerici et al., 2018; Sun et al., 
2018) and the nuclease model (CPSF100 and CPSF73). Polymerase module binds directly to 
PAS site via CPSF30 and the N terminal WD40 domain of WDR33 (Sun et al., 2018). The zinc 
fingers in CPSF30 are responsible for making contacts with RNA and other proteins (Barabino 
et al., 1997; Sun et al., 2018). CPSF73 is the endonuclease for pre-mRNA cleavage whose 
function is Zn2+ dependent. CPSF100 and CPSF73 form a dimer and they share high sequence 
homology, however, CPSF100 is endonuclease deficient because it lacks the zinc-binding 
domain (Mandel et al., 2006; Ryan et al., 2004). Some previous work also included symplekin 
as a part of the CPSF complex (Sullivan et al., 2009), however, in this work, symplekin would 
be introduced separately. 
CstF complex 
In humans, CstF complex is composed of three subunits: CstF77, CstF64 and CstF50 
(Gilmartin and Nevins, 1991; Takagaki et al., 1990; Takagaki et al., 1989). CstF complex binds 
to DSE and stimulates cleavage in 3' processing (MacDonald et al., 1994). To current 
knowledge, CstF complex assembles with two copies of each subunit in cells (Bai et al., 2007; 
Legrand et al., 2007) and associates with Pol II during elongation and termination. CstF77 
works as a bridge by interacting with both CstF50 and CstF64 (Takagaki and Manley, 2000). 
CstF64 binds to the terminal proline region of CstF77 (Hockert et al., 2010) and binds to RNA 
via its N terminal RNA recognition motif (RRM)(Perez Canadillas and Varani, 2003; Takagaki 
et al., 1992; Takagaki and Manley, 1997). CstF50 has no counterpart in yeast. N-terminal part 
of CstF50 is responsible for the dimerization of the whole complex (Moreno-Morcillo et al., 
2011; Takagaki and Manley, 2000). 
Symplekin (SYMPK) 
Symplekin is a big protein with the molecular weight of 141kDa. It is thought to be a scaffold 
protein which bridges CPSF complex and CstF complex (Keon et al., 1996). In cells, symplekin 
is tightly associated with CPSF100 and CPSF73 (Hofmann et al., 2002; Sullivan et al., 2009), so 
it might also stimulate the activity of CPSF73 (Sullivan et al., 2009). For this reason, 
symplekin is often considered a part of the CPSF complex. Symplekin forms a stable complex 
with SSU72 (Ghazy et al., 2009; Xiang et al., 2010), which is a Ser5 phosphatase of Pol II CTD, 
and stimulates its phosphatase activity.  
CFI and CFII 
The CFI complex is assembled as a heterotetramer with a dimer of the small subunit, 
CFIm25, and a dimer of the big subunit which can be CFIm59, CFIm68, or CFIm72 
(Ruegsegger et al., 1996; Ruegsegger et al., 1998). CFIm59 and CFIm68 are encoded by two 
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paralogous genes, and CFIm72 is an isoform of CFIm68 (Ruepp et al., 2011). The three big 
subunits may be functionally redundant because CFIm68 and CFIm25 are capable of 
reconstituting CFI activity in vitro (Ruegsegger et al., 1998). CFI complex binds specifically to 
USE and assists the selection of poly(A) site (Li et al., 2011; Yang et al., 2011).  
CFII is composed of Pcf11 and Clp1 in human. Human Pcf11 is twice as big as its yeast 
counterpart and they have sequence similarities only within the N terminal CTD interaction 
domain (CID domain) (de Vries et al., 2000), which binds specifically to Ser2 phosphorylated 
CTD during termination (Meinhart and Cramer, 2004). The middle domain of Pcf11 binds to 
both Pol II CTD and RNA, so this domain might bridge the CTD to pre-mRNA. In yeast, the 
CFIA complex is composed of Rna14, Rna15 (the homology of CstF complex) and Pcf11, Clp1 
(Gordon et al., 2011). However, in human CstF complex and CFI are two different complexes 
and no evidence shows that they can form a complex so far. Human Clp1 is an active 5'-OH 
polynucleotide kinase and interacts with both CPSF and CFI (Weitzer and Martinez, 2007). 
Other factors involved in termination and 3' end processing 
There are some other factors involved in 3' processing that are not a part of the above-
mentioned complexes, such as polyadenylate-binding nuclear protein 1 (PABPN1), Senataxin 
(SETX), Retinoblastoma-binding protein 6 (RBBP6) and some kinases and phosphatases 
during termination, such as CDK12/Cyclin K and Protein phosphatase 1 (PP1). PABPN1 is 
thought to bind to PAP together with poly(A) binding protein (PABP) and assist its function 
(Blobel, 1973). In early studies, it was also shown that PABPN1 binds to poly(A) tail and 
works as a ruler to decide the length of poly(A) tail together with CPSF complex and PAP 
(Kuhn et al., 2009). SETX is a huge protein in human with a molecular weight of 303kDa. It is 
believed to be a yeast sen1 homologue (Sariki et al., 2016), however, no helicase activity was 
demonstrated for SETX up to now. The exact function of SETX in termination is also not clear 
yet. RBBP6 is the homolog of yeast Mpe1 but the two proteins share very low sequence 
homology and the function of RBBP6 in 3' end processing is not clear (Di Giammartino et al., 
2014; Wagschal et al., 2012). The kinases and phosphatases are mostly working on CTD 
modifications, for example, CDK12/Cyclin K was found to peak at the 3’ end of genes (Bosken 
et al., 2014), which means it functions in the late elongation and termination and might be 
functionally overlapping with CDK7 and CDK9. SSU72 is a Ser5 phosphatase which specifically 
removes Ser5 phosphorylation during termination (Ganem et al., 2003). 
Pol II C terminal domain (CTD) and phosphorylation 
Rpb1, the largest subunit of Pol II, has the long extended C terminal domain (CTD). CTD 
consists of consensus repeats Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7, with the repeating 
number of 52 in human and 26 in yeast (Brickey and Greenleaf, 1995). CTD is unstructured 
and the function is not fully understood. During the whole transcription process, CTD is a 
target for a wide range of post-translational modifications, of which the best known is 
phosphorylation (Eick and Geyer, 2013).  
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Pol II is recruited to promoters in a dephosphorylated form. After recruitment, Ser5 is 
phosphorylated by CDK7, which is part of the transcription factor IIH (TFIIH)(Fisher, 2019). 
Ser2 phosphorylation is executed by CDK9/Cyclin T (Ctk1 in yeast). CDK9/Cyclin K composes 
the positive transcription elongation factor (P-TEFb) complex (Bacon and D'Orso, 2019), 
which plays an important role in Pol II release during promoter-proximal pausing (Vos et al., 
2018a). With Pol II moving to the end of the gene, another kinases act on CTD, such as  
CDK12/Cyclin K and CDK13/Cyclin K (Bartkowiak et al., 2010). Even though the clear function 
of these kinases is not clear yet, the concentration of CDK12 and CDK13 peaks at the end of 
the gene (Bosken et al., 2014). 
At different transcription stages, CTD has different phosphorylation states, which might be 
correlated with different protein factors being recruited to Pol II (Buratowski, 2009; Egloff 
and Murphy, 2008). The ratio of Ser2 phosphorylation and Ser5 phosphorylation (Ser5-P to 
Ser2-P) is becoming lower as Pol II goes from 5' end to 3' end of genes (Vasiljeva et al., 
2008). Proteins involved in early transcription events, such as capping, prefer to bind to 
Ser5-P. However, the 3' processing factors, prefer to bind to Ser2-P, which is a CTD-
modification enriched during late stages of transcription (Ahn et al., 2004). Ser7 
phosphorylation (Ser7-P) is another CTD modification involved in the recruitment of the 
integrator complex to snRNA encoding genes (Egloff, 2012). However, the function in mRNA 
transcription is not clear. Recent studies show that Ser7-P is present at the promoter region 
of protein coding genes and the phosphorylation level increases towards the 3' region (Kim 
et al., 2010). The function of Ser7-P in termination remains unclear. Dephosphorylation of 
Thr1 of CTD is also thought to be important in termination, which is executed by SSU72 in 






Figure 2.3: A cartoon representation of termination/3' processing factors in human Pol II 
transcription. CPSF complex, CstF complex, CFI, CFII and Pol II are colored in red, blue, 
orange, green and orange, respectively. PAP is colored in magenta. Pol II is colored in yellow. 
CTD is shown as a wavy line extending from Pol II. PAS and downstream element sequences 
are indicated above the RNA.  The cartoon is adapted from C.R.Mandel et al., cellular and 
molecular life sciences, 2008 
1.4 Pre-mRNA 3' processing in humans and aims of this work. 
As mentioned above, there are two steps in 3' polyadenylation. Firstly, the pre-mRNA is 
cleaved at the cleavage site, which is defined by the 3' processing factors and the three 
elements in the pre-mRNA. There might also be some auxiliary elements on the pre-mRNA, 
located further downstream or upstream from the cleavage site (Zhao et al., 1999). CPSF73 
is the endonuclease which performs the pre-mRNA cleavage (Mandel et al., 2006). The 
second step is the polyadenylation process, in which the polymerase PAP adds a poly(A) tail 
to the 3' end of the RNA by using ATP. There are at least four different types of PAP in 
metazoans, including PAP, Neo-PAP, Star-PAP, and tPAP (Edmonds, 1990). PAP is most 
widespread in human. The length of poly(A) tail is determined by the crosstalk between the 
poly(A) binding protein, PAP and CPSF (Kuhn et al., 2009). Some studies showed that the 
length of poly(A) tail is determined by how many copies of poly(A) binding protein bind to 
the poly(A) tail. PABPN1 is the poly(A) binding protein in the nucleus and one copy of 
PABPN1 binds to ~30nt of RNA (Wahle, 1995). Also, the binding of PABPN1 facilitates the 
function of PAP (Wahle, 1995). Thus, the coordination of PAP and PABPN1 determines the 
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length of poly(A) tail. The length of poly(A) is correlated with the stability of both mRNA and 
protein. 
For many years, the structure study of termination/3’ processing factors was limited to 
truncated subunits or domains, which includes the HAT-N domain of CstF77 (Bai et al., 
2007), dimerization domain of CstF50 (Moreno-Morcillo et al., 2011), Pcf11 CID domain 
(Meinhart and Cramer, 2004) etc. There are also some crystal structures of protein 
complexes like CFIm68/25 (Yang et al., 2011). But for most sub-complexes, the subunits 
arrangement inside the complex is not clear because the crystallization of big proteins or 
protein complexes is difficult, or because the complex itself is too dynamic for structural 
studies. In the last few years, with the improvement of cryo-EM in both hardware and 
software, the structures of big complexes were possible to be solved to near atomic 
resolution without crystallization. In the 2017 and 2018, the CPF polymerase module from 
yeast (Casanal et al., 2017) and CPSF polymerase module from human (Clerici et al., 2017; 
Clerici et al., 2018; Sun et al., 2018) were solved by both crystallography and EM 
respectively. The polymerase module of CPSF (in human) and CPF (in yeast) are quite similar: 
the three ß-propellers of CPSF160 (BPA, BPB and BPC) are organized like a trefoil with 
WDR33 sitting on top of BPA and BPC (Casanal et al., 2017; Sun et al., 2018). The structures 
also revealed that CPSF polymerase module recognizes specifically the PAS site. WDR33 N-
terminal domain and CPSF30 have direct interaction with the AAUAAA sequence (Sun et al., 
2018). This is a breakthrough for the study of 3’ processing and can be used as a starting 
point for future studies. 
So far, there are still quite some questions to be answered about 3’ processing and 
termination, which includes how the pre-mRNA cleavage site is defined, how the cleavage 
occurs, what the working mechanism of CPSF73 and PAP is, and how the 3’ processing is 
coordinated with termination. All these questions are challenging for structure studies as the 
termination and 3’ processing might be very dynamic processes.  This means it will be 
challenging to lock the complex in a stable state suitable for structure analysis. 
In this study, I am trying to reveal the mechanism of termination/3’ processing by using in 
vitro reconstitutions, cryo-EM, crystallography and biochemical assays. To get enough 
proteins for in vitro studies, I expressed and purified all canonical factors involved in 3’ 
processing/termination. These factors were expressed and purified as defined complexes, 
such as CstF complex, CFI and CFII. The CPSF complex was divided into 2 modules: the 
polymerase module (CPSF160, WDR33, Fip1 and CPSF30) and nuclease module (Symplekin, 
CPSF100, CPSF73). These two modules were expressed and purified individually. Whether 
symplekin is one of the subunits of CPSF complex is still under debate. However, earlier 
studies showed that symplekin forms a stable complex with CPSF100 and CPSF73 (Sullivan et 




The structure of CPSF polymerase module was solved in the last two years. However, the 
endonuclease responsible for the pre-mRNA cleavage, CPSF73, was not included in the 
complex. Even earlier studies showed that CPSF73 alone had the nuclease activity (Mandel 
et al., 2006). It is still unknown how CPSF73 works in the full CPSF complex, and what the 
stimulation mechanism of the nuclease activity is, and also how the polymerase module and 
nuclease module coordinate during the cleavage process. 
In this work, I assembled the full CPSF complex (including symplekin) with purified CPSF 
polymerase and nuclease modules, and I analyzed the complex by both negative staining and 
cryo-EM. In parallel, I tried to investigate the cleavage activity of the complex in vitro and 
compared it with CPSF73 activity alone. However the cleavage activity assay turned out to be 
tricky and more experiments need to be done. Combining both structural studies and 
biochemistry, I am trying to understand the role for CPSF complex in 3’ processing. This work 
would show the progress so far. 
In parallel, I attempted to crystallize the CstF complex, which was previously not possible 


















2 Materials and Methods 
2.1 Materials 
2.1.1 Bacterial strains and cell lines  
Species  Strain/cell lines  Genotype /origin  Supplier  
E. coli  XL1-Blue  recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F’ proAB 
lacIqZ∆M15 Tn10 (Tetr)]  
Agilent  
E. coli  BL21-Codon  
Plus(DE3)-RIL  
E. coli B F- ompT hsdS(rB- mB-) 
dcm+ Tetr E. coli gal λ (DE3) endA 
Hte [argU ileY leuW Camr]  
Agilent  
E. coli  DH10EMBacY  F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80dlacZ∆M15 ∆lacX74 endA1 
recA1 deoR ∆(ara, leu)7697 
araD139 galU galK λ- rpsL nupG / 
bMON14272‡ yfp+/ pMON7124  











Sf9 immortalized pupal ovarian tissue 
cells, clonal isolate of parental cell 





Hi5 (High Five)  
(BTI-TN-5B1-4)  





2.1.2 Chemicals and kits 
Name  Application Company 
General chemicals Buffers etc. Merck, Roth, Sigma-
Aldrich  
Enzyme additives and 
other reagents 
Cloning Fermentas, New England 
Biolabs (NEB), Promgea  
Plasmid preparation kit Plasmid extraction from 
E.coli 
QIAGEN  
Gel extraction kit Gel extraction of linearized 






2.1.3 Additives for E. coli and insect cell culture. 
Additives Application 1000x Stock 
Ampicillin  Antibiotic for E.coli culture 100 mg/mL in ddH2O  
Kanamycin Antibiotic for E.coli culture 50 mg/mL in ddH2O  
Chloramphenicol Antibiotic for E.coli culture 30 mg/mL in ethanol 
Spectinomycin Antibiotic for E.coli culture 50 mg/mL in ddH2O  
Gentamycin  Antibiotic for E.coli culture 10mg/mL in ddH2O  
Streptomycin  Antibiotic for E.coli culture 30 mg/mL in ddH2O  
IPTG  expression induction  1M in ddH2O (the working 
concentration varies from 0.5 to 1mM 
X-Gal  blue-white selection  150 mg/mL in DMSO  
 
2.1.4 Buffers and solutions 
Buffer  Composition/Description (Supplier)  Application  
4x SDS-PAGE  
loading dye  
45% (v/v) glycerol, 280mM Tris pH 6.8 at 
20°C, 8% (w/v) SDS, 10% (v/v) β-




running buffer  
20x NuPAGETM MES/MOPS SDS running 
buffer (Invitrogen)  
SDS-PAGE  
gel staining  InstantBlue (Expedeon)  Coomassie staining  
PCR master mix  2x Phusion® High-Fidelity PCR Master Mix 
(NEB)  
PCR 
6x DNA loading 
dye  
Gel Loading Dye, Purple (NEB)  agarose gel  
electrophoresis  
10x TAE  50mM EDTA pH 8.0 at 20°C, 2.5M Tris-
acetate  
agarose gel  
electrophoresis  
NEBufferTM 3.1  50mM Tris-HCl pH 7.9 at 25°C, 100mM 
NaCl, 10mM MgCl2, 0.1mg/mL BSA (NEB)  
restriction 
endonuclease digest  
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CutSmart® buffer  20mM Tris-acetate pH 7.9 at 25°C, 50mM 
potassium acetate, 10mM magnesium 
acetate, 0.1 mg/mL BSA (NEB)  
restriction 
endonuclease digest  
T4 polymerase 
buffer  
10 mM Tris-HCl pH 8.0 at 25°C, 500mM 
NaCl, 100mM MgCl2, 10mM DTT  
LIC cloning 
T4 DNA ligase 
buffer 
50mM Tris-HCl pH 7.5 at 25°C, 10mM 
MgCl2, 1mM ATP, 10mM DTT (NEB)  
ligation 
P1 50mM Tris-HCl pH 8.0 at 25°C, 10mM EDTA, 
100μg/mL RNase A (QIAGEN)  
Bacmid isolation 
P2 200mM NaOH, 1% SDS (QIAGEN)  Bacmid isolation 
N3 4.2M Gu-HCl, 0.9M potassium acetate pH 
4.8 (QIAGEN)  
Bacmid isolation 
DPBS 138mM NaCl, 2.7mM KCl, 8.1mM Na2HPO4 
pH 6.9, 1.47mM KH2PO4 pH 6.9  
Insect cell culture 
X-treme 
GENETM 9  
supplied in 80% ethanol, final concentration 
1.5 μL/mL  






50mM Tris-HCl, 100mM NaCl, 20mM β-ME, 
1 mM EDTA, 50% Glycerol, 0.1% Triton® X-
100 pH 7.9 @ 25°C  
In vitro transcription 
5x Transcription 
buffer 
200mM Tris-HCl, 30mM MgCl2, 5mM DTT.10 
mM spermidine (pH 7.9 @ 25°C)  
In vitro transcription 
NTP set  100mM ATP, UTP, CTP, GTP In vitro transcription 
10xTBE buffer 
(Sigma-Aldrich) 
890mM Tris, 890mM boric acid, 20mM 
EDTA. 
Urea gel 
2x RNA Loading 
buffer (NEB) 





50mM Tris-HCl pH8.0@20°C, 10mM EDTA 
(pH8.0), 50mM Glucose, 0.01mg/ml Dnase 
free Rnase A 
Maxiprep 
Lysis solution 0.2M NaOH, 1% SDS Maxiprep 
Neutralization 
solution 
4M KOAc pH5.5 (pH with acetic acid) Maxiprep 
3M sodium acetate pH 5.2 RNA extraction 
Phenol-Chloroform-Isoamyl alcohol (25:24:1) DNA Precipitation 
Gibco® Sf-900TM 
III SFM  
low-hydrolysate, serum-free, protein-free,  
animal origin-free insect cell culture  
medium/Thermo Fisher Scientific  








ESF921TM  serum-free, protein-free insect cell culture  
media, supplemented with L-glutamine and  
Kolliphor® P188 / Expression Systems  
Hi5 culture (growth 
and maintenance of 
suspension cultures;  
uranyl formate 
solution  
2% (w/v) uranyl formate in ddH2O  negative staining     
LB 1% (w/v) tryptone, 0.5% (w/v) yeast extract,  
0.5% (w/v) NaCl (1.5% (w/v) agar for solid 
plates)  
E. coli culture  
 
2.1.5 cDNAs origins of 3' processing factors and corresponding yeast genes 
Gene name cDNA origin cDNA vector 
selection Marker 
Yeast homolog 





WDR33 (1-572aa) gblock from IDT -- Pfs2  
CPSF30(CPSF4)  Harvard medical school 
database 
HsCD00367627 
Spectinomycin  Yth1  
Fip1  gBlock from IDT  -- Fip1 
CPSF100(CPSF2)  Harvard medical school 
database 
HsCD00379114 
Spectinomycin Ctf2/Ydh1  
CPSF73(CPSF3)  Harvard medical school 
database 
HsCD00334392 
Chloramphenicol  Ysh1(Brr5) 
symplekin(SYMPK)  Harvard medical school 
database 
HsCD00045464 
Chloramphenicol Pta1  
PAP gBlock from IDT -- Pap1 
PPP1CB  Harvard medical school 
database 
HsCD00005414 
Kanamycin  Glc7  
PPP1CC  Harvard medical school 
database 
HsCD00005169 
Ampicillin   
SSU72 gBlock from IDT -- Ssu72 
Pcf11 MRCPPU Ampicillin  Pcf11 
Clp1  Harvard medical school 
database 
HsCD00378275 
Spectinomycin  Clp1 
CstF77  Harvard medical school 
database 
HsCD00339748 
Ampicillin  Rna 14  
CstF64 Harvard medical school 
database 




CstF50 Harvard medical school 
database 
HsCD00322461 
Chloramphenicol  -- 
CFIM68(CPSF6)  Amplified from genome 
cDNA 
-- -- 








CyclinK(CCNK) Harvard medical school 
database 
HsCD00327466 
Ampicillin  CyclinK(CCNK) 





2.1.6 Buffers for protein purification 
Name of buffers  Composition 
Lysis Buffer 20mM Hepes-NaOH pH7.4@20 °C, 300mM NaCl, 30mM 
Imidazole, 10% glycerol, 1mM/5mM DTT (or 0.5mM TCEP), 1x 
protease inhibitor 
Ni Elution Buffer  20mM Hepes-NaOH pH7.4@20°C, 300mM NaCl, 500mM 




20mM Hepes-NaOH ph7.4@20°C, 300mM NaCl, 30mM 
Imidazole, 117mM maltose, 10% glycerol, 1mM/5mM DTT (or 
0.5mM TCEP), 1x protease inhibitor 
Gel Filtration Buffer 20mM Hepes-NaOH ph7.4@20°C, 300mM NaCl, 10% glycerol, 
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2.2.1 Polymerase Chain Reaction (PCR)  
Polymerase chain reaction (PCR) was used to amplify DNA fragments from different cDNA 
templates. 50ul reaction was set up including 10 to 250ng template DNA, 0.5μM forward 
and reverse primer respectively, 200μM of dNTP mix and 1U of Phusion or Q5 polymerase 
(NEB). Thermo cycling was set up with 3 minutes of denaturation at 95 or 98 °C depending 
on the polymerase, 30 seconds denaturation (95 or 98°C), 30 seconds primer annealing (The 
primers were designed to have an annealing temperature of 55 to 60°C). Extension time was 
set according to the length of the target DNA, typically 30s for 1kb. The whole PCR program 
includes 35 cycles and finalized with 10 minutes elongation at 72 °C.    
2.2.2 Agarose Gel Electrophoresis and Gel Extraction  
The DNA fragments generated from PCR or restriction enzyme digested vector need to be 
separated by electrophoresis in 1% (w/v) agarose gels. 1g agarose was dissolved in 100ml 1x 
TAE buffer by heating in the microwave. 2ul of SYBRTMSafe DNA Gel Stain (Invitrogen) was 
added. The 'agarose solution' was poured into the gel chamber and left at room 
temperature for at least half hour to solidify. The prepared gel was covered with 1xTAE 
buffer and ready for sample loading. The PCR product or linearized vector was mixed with an 
appropriate amount of 6x DNA Loading Dye (NEB) and loaded onto the gel together with a 1 
kb DNA Ladder size standard (NEB)(or 100bp marker based on the size of the product). The 
gel was run at 120V for 20 to 30 minutes till a sufficient separation of different fragments 
and then imaged with a UV imager. Bands with the target size was cut and extracted 
according to the gel extraction kit protocol (QIAGEN). Briefly, 3 volumes of buffer QG was 
added to the gel and incubated at 50°C till it dissolved completely (check in between and 
invert up and down for a few times). Then 1 gel volume of isopropanol was added and mixed 
thoroughly. The dissolved DNA was applied to the column and washed with 750ul PE buffer. 
The column was spun down at the maximum speed for 1 minute to remove the ethanol 
before the DNA fragments were eluted with 50ul ddH2O. Normally the water for elution was 
heated up to 65°C to improve the elution efficiency. 
 
2.2.3 Preparation of chemically competent E.coli cells 
Cells from old aliquot or commercialized origin were plated on LB agar plate with 
appropriate antibiotics and cultured overnight at 37°C incubator. The next day, single colony 
was picked and cultured in LB medium with corresponding antibiotics at 37°C overnight (16 
to 18 hours). 5ml MgCl2 and appropriate antibiotics were added to 1 liter pre-warmed SOB 
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medium. The overnight E.coli culture was added to the medium at a 1: 250 dilution ratio. 
The cells were cultured at 37°C while shaking till the OD600 reached to 0.5 to 0.6. Then the 
cell culture was transferred to the 250ml conical wide-mouth centrifuge tubes 
(Thermoscientific) which were pre-chilled on ice. The cells were incubated on ice for 10 min 
in the centrifugation tubes and then spun down at 3000g for 10 min at 4°C. The supernatant 
was carefully discarded and the pellet was re-suspended in 75ml of inoue buffer per 250ml 
cells. The re-suspended cells were incubated on ice for 10 min. Again the cells were spun 
down at 3000g at 4°C for 10 min. The supernatant was carefully discarded and the cells were 
re-suspended in 10ml of inoue buffer per 250ml cells. 700ul DMSO was added drop by drop 
to the 10ml cells while shaking. The cells were kept on ice for 10 min and aliquoted as 100ul 
aliquots in 1.5ml tubes (Eppendorf), snap-frozen in liquid nitrogen and stored at -80°C for 
using. To make sure the transformation efficiency is high and no contamination was 
introduced during the preparation process, one quality control by transformation is 
necessary.  
2.2.4 Preparation of electrocompetent E.coli cells  
The E.coli cell culturing was the same as the chemically competent cells except for that the 
DH10αEMBacY cells were used. The cell pellet was washed two times with pre-chilled 
sterilized ddH2O and one time with 10% (v/v) glycerol. Then the cells were re-suspended in 
10% glycerol, aliquoted as 100ul fractions in 1.5ml eppendorf tubes, flash-frozen in liquid 
nitrogen and stored in -80°C. 
2.2.5 Ligation-independent cloning (LIC) 
Ligation-independent cloning (LIC) is a new strategy for cloning, which is faster and more 
efficient than the traditional method. LIC cloning depends mostly on T4 polymerase (LIC- 
qualified, Novagen), which has both an exonuclease and a polymerase activity. In the 
absence of substrate dNTPs, T4 polymerase ‘chews’ back the ends of double strand DNA and 
generates overhangs. However, to prevent the 3’-5’ exonuclease activity from continuing 
indefinitely, Addition of specific dNTPs is necessary, which would restrict the 3’-5’ 
exonuclease processivity to the site of the first matching DNA base on the complimentary 
strand (Supplementary figure 1A). MacroBac Series-438 vectors were designed to comprise a 
LIC-compatible site for the insertion of ORFs, which is exposed after cleaved with SspI. The 
complimentary overhangs permit the annealing of vectors and inserts but prevent internal 
annealing. The PCR fragment and the linearized vector were treated with T4 polymerase 
separately. 20ul of reactions were set, which comprised of 150 ng of linearized DNA (vector 
or insert), 2.5 mM of the respective dNTPs (dCTP for inserts and dGTP for vectors), 5mM 
DTT, 2μL of 10x T4 DNA Polymerase buffer (NEB) and 2U of T4 polymerase (Novagen). The 
reaction system was incubated at 25°C for 40 min followed by the enzyme heat inactivation 
at 75 °C for 20 min. For annealing after T4 polymerase treatment, 2μL (50 to 100ng) of 
vector and 2μL of insert DNA were mixed (the volume can also be 4ul and 4ul if the inserts 
are long or the concentration of the fragments are low) and incubated at 25°C for 30 min. 
The rest of the T4 polymerase treated DNA can be stored at -20°C for future use. Reactions 
were stopped by adding 1.3μL of 25mM EDTA and incubated for 10 min at 25°C. The 
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complete reaction volume was directly transformed into XL1-Blue chemically competent 
cells. 
2.2.6 Sequence and Ligation-Independent Cloning (SLIC) 
SLIC cloning method is similar to LIC cloning. Both LIC and SLIC need T4 polymerase for its 
exonuclease and polymerase activity. The only difference is that no dCTP or dGTP would be 
added into the SLIC reaction. Comparing with LIC, SLIC doesn’t have very exact overhangs for 
annealing. The linearized vector, the insert prepared by PCR, T4 DNA polymerase and 
corresponding reaction buffer were mixed and kept at room temperature for 10 minutes to 
generate the overhang and anneal the two fragments. Then the reaction was transferred on 
ice for another 10 minutes and transformed directly to XL-blue chemically competent cells. 
2.2.7 Transformation of chemically competent E.coli 
Plasmid or DNA ligation reaction was mixed with 100ul of chemically competent E.coli cells 
and incubated on ice for 30 minutes. Cells were heat shocked at 42°C for 70 seconds and 
kept on ice for another 3 minutes. 1ml of LB was added to the cells and the culture was 
recovered at 37°C for 45 minutes to 2 hours. After recovery, the cells were spun down at 
13,000 rpm for 1min. The supernatant was gently removed and 100ul of fresh LB medium 
was added to the pellet. The cells were re-suspended and plated on the LB agar plate plus 
corresponding antibiotics. The plate was cultured at 37°C incubator. 
2.2.8 Concatenation of poly-promoter MacroBac Series-438 vectors containing 
multiple ORFs  
After inserting ORF of each gene to 438 serials vector, the next step is to connect these 
genes on one vector with their own promoters and terminators. Because each gene has its 
independent promoter and terminator, the order for connection doesn't matter. The 
acceptor vector would be linearized with SspI, while the donor vector would be digested 
with PmeI, which would end up with 2 fragments, the one with the target ORF and 
corresponding promoter and terminator would be used for ligation (supplementary Figure 
1B). Again LIC was used for the ligation of acceptor and donor vectors. dCTP was added to 
the donor vector reaction while dGTP was added to the acceptor reaction. After the 
treatment with T4 polymerase, the donor and acceptor vector were annealed and 
transformed into XL1-Blue cells following the standard LIC protocol. 
2.2.9 Site-directed mutation correction 
QuickChange approach was used to correct the mutations in the target vector which came 
from the cDNA or were introduced by the cloning process (UV light). Forward and reverse 
primers with correct sequences were designed to amplify the dsDNA from the same site 
around the mutation site, one of the two primers need a 5’ phosphate group for the later 
ligation reaction. After amplification, the PCR reaction was treated with Dpn I at 37°C for at 
least two hours to remove the parental plasmid. The PCR product was then purified by 
agarose gel extraction. The purified DNA was ligated with T4 ligase (ThermoScientific) and 
transformed to XL1-Blue cells. For T4 ligation, 10ul reaction was set up with 20 to 100ng DNA 
fragments plus 1ul 10 x buffer and 1U T4 ligase. The reaction was kept at room temperature 
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for 10 minutes and transferred to ice for 3 minutes and then transformed to the competent 
cells. 
2.2.10 Introduction of the multi ORFs into baculovirus shuttle vectors (bacmid 
Preparation)  
The blue white screening method is a classical screening method. The method is based on 
the β-galactosidase gene for its α-complementation function. The β-galactosidase in the host 
E.coli strain was not active because the deletion of the first 41 amino acids, however this can 
be remedied by the expression of the first 59 amino acids by introducing one vector, the 
short peptides is named as α-peptide and the rescue of β-galactosidase activity is called α-
complementation. X-gal is colorless, however, within the induction of IPTG, X-gal can be 
cleaved to form a blue pigment 5,5'-dibromo-4,4'-dichloro-indigo, which would make the 
whole colony look bright blue. For the blue white screening design, multiple cloning sites 
were introduced to the α-peptide coding area. If the target fragment was successfully 
introduced to the vector, the expression of α-peptide was destroyed and the β-galactosidase 
was inactivated, then the colony would end up with a white color, which can be 
differentiated from the negative blue colonies. 
The final 438 series vector which includes all target ORFs was transformed into the 
DH10Multibac cells. This E.coli strain features the respective viral genome on a bacmid 
vector, and the transformed vector can be transferred to the genome by gene transposition. 
1µg of the construct plasmid was added to 200µL electrocompetent DH10Mutibac cells and 
kept on ice for 15 minutes. Then the cells were transferred to electroporation cuvette to 
execute the electroporation (one pulse, 25 μF, 1.8 kV). 1mL LB medium was added and the 
whole system was transferred to 15mL culture tube to grow for 5 hours to overnight while 
shaking at 37˚C, because the cells need some time for transposition. After recovery, 25 to 
100ul cells (based on the transformation efficiency, which is normally quite efficient) were 
plated to the X-gal plates. The X-gal plates are normal LB agar plates with 150 ug/mL X-gal, 
1mM IPTG and 10ug/mL gentamycin. After 36 to 48 hours incubation, there should be 
obvious blue/white colonies on the plate. At least three of the white colonies should be 
picked. The white colonies were plated on a new X-gal plate and cultured for another 24 to 
48 hours to exclude false-positive colonies. The white colony was cultured at 37°C overnight 
in 4~6ml LB medium plus gentamycin for bacmid preparation. For bacmid extraction, the 
miniprep kit was used and the first several steps were the same as miniprep. After adding N3 
and spun down for 10min at 15,000rpm. The supernatant was transferred to a new 1.5ml 
tube and 700µL isopropanol was added. After mixing with votex, the tube was incubated at -
20˚C for 5 hours or -80°C for 2 hours to precipitate the DNA. Afterwards the tube was taking 
out and the DNA was spun down by centrifugation at maximum speed for half hour. After 
centrifugation, the supernatant was trashed while the pellet was washed with 500µL 70% 
ethanol. After centrifugation for 10 minutes at the maximum speed, the ethanol was 
carefully removed. 30ul ethanol was left on top of the pellet till transfection. 
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2.2.11 Bacmid transfection to sf9 cells and V0 production 
All transfection steps were operated in Biological Safety Cabinets. The ethanol on top of the 
bacmid was removed gently and the pellet was left in the hood for 5 to 10 minutes with the 
lid open for ethanol evaporation. 20µL water was added to the top of the pellet gently and 
the lid was then closed, pipetting to re-suspend pellet was not allowed because this would 
shear the bacmid. To dissolve DNA, Incubation with water for 10-20 minutes is necessary. A 
mastermix can be prepared during the incubation time, which contains 10ul of Xtreme Gene 
9 transfection agent and 100ul Gibco® Sf-900TM III SFM for each bacmid transfection. 200ul 
of sf9 media was added to the dissolved bacmid DNA plus 100µL of transfection agent 
master mix. The whole reaction system was incubated for 60 minutes. Again pipetting up 
and down was not allowed, the medium and mastermix should be added to the bacmid 
gently. During the incubation time, the sf9 cells were prepared in a 6 well plate. Each well 
was either filled with 3ml sf9 cells with the density of 1E6 or 3ml medium as control. For one 
transfection, there should be at least one medium control and one cell control to make sure 
that both the medium and the cells were not contaminated. After pipetting cells into the 
wells, the plate was gently shaken manually to make sure that the cells are distributed as 
‘single-layer’ at the bottom of the plate. After one hour, the bacmid mixture was added to 
the corresponding wells drop by drop. Normally two wells were used for each bacmid strain 
(Supplementary figure 2). The plates were incubated at 27°C for 48 to 72 hours. Cells were 
checked with fluorescent microscope to track the ‘green cells’ because successfully 
transfected cells would express YFP which is visible under fluorescent microscope. The 
‘green cells’ should begin to appear after 48 hours. V0 should be harvested maximum 72 
hours after transfection. For harvesting, the supernatant was carefully sucked with pipette 
tubes and stored in 15ml Falcon tubes. The prepared V0 were marked with date, cell type 
and name of bacmid etc.  
2.2.12 V1 production and virus propagation 
To amplify V0 and make the expression more efficient, V1 was made with sf21 cells. 25 mL of 
sf21 cells with a density of 1.0×106 cells/ml was infected with 50ul to 1ml V0 (based on the 
number of green cells during V0 production, more green cells mean stronger virus). For the 
culture of sf9 cells and sf21 cells, the flask should have ten times more volume (for example, 
a 500ml flask can hold maximum 50ml culture, if the volume of the cells was over 50ml after 
dilution, the extra cells should be either trashed or transferred to a new flask).The cells were 
cultured at 27°C while shaking at 60rpm. The cell culture should be checked every 24 hours 
about its density, viability and diameter.  The density of the cells should double after 24 
hours, but not change so much afterwards, which was named as the day after proliferation 
(DPA). The density of cells should be kept at 1.0×106 cells/ml every day. After the viability 
dropped below 88 percent, the virus should be harvested, which was normally 48 to 72 
hours after DPA depending on the activity of the virus. V1 was harvested by centrifugation at 
250g for 15 minutes at 4 °C. The supernatant was transferred to a new 50ml Falcon and 
stored at 4°C for expression. The virus should be marked with name, date and cell type. The 
pellet can be kept at -20°C for pull down assay of the expression. 
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2.2.13 Protein expression in Hi5 cells 
600ml Hi5 cells were cultured to a density of 1.0 × 106 cells/ml in a 3L flask, 300ul to 1ml V1 
(based on the viability of V1) was added to the Hi5 cells and cultured at 27°C while shaking at 
60rpm. The cells need to be checked every 24 hours for their viability, diameter and activity. 
Normally the DPA reached the next day after transfection, which means more medium 
should be added to keep the density at 1.0 × 106 cells/ml. For the next few days, the 
population activity of the cells should be more than 90%. The cells should be harvested if the 
activity dropped below 88% to make sure the protein expression was at the peak and the 
protein was not degraded because of cell death. However, if the density of cells was not 
double in the next day or the cells kept dividing, one should think about changing the 
infection volume of V1. For some proteins which are not so stable and can be degraded 
easily, the cells should be harvested in 24 to 48 hours to avoid degradation. 
2.2.14 Protein expression in E.coli 
Vector with target gene was transformed into E.coli BL21 competent cells and plated to LB 
plate with corresponding antibiotics. Single colony was picked after 16 to 18 hours and 
cultured in LB medium with corresponding antibiotics at 37°C overnight. 2L of LB plus 
antibiotics was prepared and the overnight culture was added to the flask to an OD600 of 
~0.2. The E.coli was cultured at 37°C for 3 to 4 hours till OD600 arrived to 0.6 ~ 0.8. For Zinc 
finger protein, 0.2mM ZnCl2 was added and incubated at 37°C for another 15 to 30 minutes. 
Afterwards, the flask was taken out from 37°C shaker and cooled down on ice for 20 
minutes. Then 0.25mM to 1mM IPTG was added and the expression was performed at 37°C 
for 3 hours or 18°C overnight while shaking at 160rpm. The cells were harvested by 
centrifugation at 4000 rpm for 15 min. The pellet was re-suspended in Lysis buffer, flash 
frozen in liquid nitrogen and kept at -80°C for purification. 
2.2.15 General purification of protein complexes 
One of the subunits of the protein complex was designed to have an N terminal His-MBP tag. 
The purification was done by two rounds of affinity purification (Ni and maltose) and one 
round of gel filtration. The harvested cells with their lysis buffer were taken out from -80°C 
and thawed in water bath which was kept at room temperature. The thawed cell suspension 
was transferred to a metal beaker for sonication (3 min at 30 % output with ON = 0.6 s and 
OFF = 0.4 s). The sonicated lysate was transferred to oak ridge centrifugation tubes for rotor 
A27 and spun down at 27,000 rpm for 30 minutes. The supernatant was transferred to ultra- 
centrifuge tubes for Ti-45 rotor and spun down at 45,000 rpm for 1 hour. Then the 
supernatant was collected and filtered with syringe filter for loading.  HisTrap HP 5 mL 
column (GE healthcare) was washed with water for 10 column volumes and equilibrated in 
lysis buffer ready for loading. The supernatant was loaded to Ni column with peristaltic 
pump at a slow flow rate. At the same time, the Amylose column (Home made with amylose 
resin from NEB) was equilibrated in lysis buffer with Äkta system (GE healthcare) at the flow 
rate of 1ml/min. After loading, the Ni column was transferred to Äkta system, washed with 
50ml of lysis buffer and then connected with amylose column (Supplementary figure 3). The 
protein was eluted to amylose column with Ni elution buffer. In this step, the target protein 
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bound to the amylose column while the random protein came out. After elution, the Ni 
column was disconnected and the amylose column was washed with lysis buffer till the 
baseline reached. The protein was eluted from amylose column with amylose elution buffer. 
The elution was collected with 96 well plates with 1ml volume fractions. The peak fractions 
were picked and loaded to the SDS-PAGE gel. According to the gel, target fractions were 
pooled and collected for further purification. TEV and lamda phosphatase were added to the 
protein at a ratio of 1:5 and 1:20 respectively. The whole solution was dialyzed overnight 
with Thermo Scientific SnakeSkin 7K MWCO dialysis bag to 1L lysis buffer plus 1mM MnCl2 
(as the lamda phosphatase need Mn2+ to be active). The protein was taken out from the 
dialysis bag the next morning and loaded to the pre-equilibrated Ni column with peristaltic 
pump. This step would help to separate TEV and MBP from target protein. Because TEV and 
MBP bound to the Ni column (there is one his tag on TEV) while the target protein came out 
from the flow through after his-MBP cleavage overnight. Lysis buffer was used to wash the 
column to make sure that all the target protein comes out from the column. Bradford 
solution was used to track the flow and to decide where to stop the collection. The column 
was eluted with Ni elution buffer afterwards and the elution was collected (because some 
tags were not cleavable and some protein binds to Ni column itself, both the flow through 
and elution should be collected for later SDS-PAGE identification).  Fractions from overnight 
dialysis, flow through and elution were loaded to SDS-PAGE to figure out the fractions of the 
target protein. If the MBP-His tag was not cleavable, the target protein would come out from 
the elution together with TEV-MBP, which needs to be separated by further gel filtration 
afterwards. The target protein from the reverse Ni step would be concentrated with Amicon 
Ultra-15 centrifugal filter unit (100-kDa molecular mass cut-off) (Merck) to 0.9ml, spun down 
by centrifugation at 15,000rpm for 10 minutes and loaded to Superose 6 increase 10/300 
column (GE healthcare) which was equilibrated with gel filtration buffer beforehand. The 
peak fractions from gel filtration were identified by SDS-PAGE gel, the target protein 
fractions were pooled together and concentrated with Amicon Ultra-15 centrifugal filter unit 
(100-kDa molecular mass cut-off). The concentration was checked from time to time during 
concentration. The final concentration of the protein complex was controlled to 30~50uM. 
The protein was aliquoted as 6ul aliquots and flash frozen in liquid nitrogen. The aliquots 
were stored at -80°C marked with date, name and concentration etc. 
2.2.16 Mxiprep 
The RNA for in vitro cleavage assay was produced with T7 RNA polymerase (NEB) by in vitro 
transcription. To get enough template DNA for transcription, the vector carrying the DNA 
template needs to be prepared by maxiprep. The E.coli cells which carried the target vector 
were cultured in 250ml LB with corresponding antibiotics at 37 °C overnight. The overnight 
culture was spun down at 4000rpm for 15 minutes with F14 rotor. The pellet was re-
suspended in 12ml resuspension buffer and transferred to a 50ml falcon tube, 12ml lysis 
buffer was added and the tube was inverted 4 to 8 times. To make the lysis of the cells more 
efficient, the falcon was left at room temperature for 5 minutes. The reaction was quenched 
with 12ml neutralizing solution and inverted 4 to 8 times. The tube was centrifuged for 30 
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minutes at 4000rpm at 4°C. The supernatant was transferred to a fresh 50ml Falcon with 
25ml 25:24:1 phenol:chloroform:isoamylalcohol (Merck)(all the operations with organic 
solvent were performed in the hood). The solution was inverted 4 times and spun down for 
30 minutes at 4000rpm at 4°C. The supernatant was transferred to a new 50ml falcon with 
25ml chloroform. The solution was inverted 2 times and spun down for 30 minutes at 
4000rpm at 4°C. Again the supernatant was carefully pipetted out and transferred to a new 
50ml falcon with 25ml 100% ethanol. 2.5ml 3M sodium acetate pH5.2 was added and the 
whole tube was transferred to -80°C for one hour. The DNA was then spun down for 30 
minutes at 4000rpm at 4°C. The supernatant was discarded and the pellet was washed with 
70% ethanol and spun down at 4000rpm for 15 minutes. The pellet was dried for 5 minutes 
and re-suspended in 1ml RNase free water. The concentration was checked with nanodrop 
and marked on the tube for future use.  
2.2.17 Template DNA linearization by Hind III 
Template vector for in vitro transcription needs to be linearized with Hind III to avoid 
supercoil in transcription. 1mg vector was digested in 1ml reaction system (150ul of 
20,000U/ul Hind III-HF with 1× Cutsmart buffer, from NEB) at 37°C overnight. The next day 
phenol chloroform reaction was used to remove remaining restriction enzyme and isolate 
the linearized DNA. 100µL RNase free NaAc 3M was added to the 1ml reaction digestion 
followed by 1mL Phenol-Chloroform-Isoamyl alcohol (25:24:1). The solution was transferred 
to phase lock tube and spun at maximum speed for 10 minutes at 4°C. The upper aqueous 
phase was transferred to a fresh tube with 1000µL chloroform. The solution was Vortexed 
and transferred to phase lock tube and spun down at 4°C for 10 minutes at 15,000 rpm. 
Again aqueous phase was transferred to fresh tube. 700µL isopropanol (0.7 vol) was added 
and Incubated at -20°C for 1 hour to precipitate DNA. The DNA was pelleted by 
centrifugation and re-suspended in 70µL RNase free ddH2O. The concentration was checked 
and marked on the tube for future use. 
2.2.18 RNA production by in vitro transcription 
1mL in vitro transcription reaction include 200µL of 5x Transcription buffer, 1µL  Triton X-100 
(1% w/v solution), 24µL MgCl2 (1M) , 40µL ATP (100mM stock), UTP, CTP, GTP respectively, 
100µg linearized DNA and 17.4µL T7 RNA polymerase (T7 RNA polymerase, transcription 
buffer and NTP set were all from NEB. All the other materials were RNase free). The reaction 
was kept at 37°C overnight (maximum 16 hours) while shaking at 350rpm. The RNA was 
precipitated the next day. Each in vitro transcription reaction was split into two tubes (500µL 
per tube). 80ul of 0.5M EDTA pH 8.0 was added to each tube to dissolve MgPP formed 
during the in vitro transcription. 35µL 5M NaCl and 430µL isopropanol was added to 
precipitate the nucleotides. To make the precipitation more efficient, the reaction was 
normally incubated at -80°C for 2 hours. After thawing, the solution was centrifuged at 
13000 xg for 30 minutes at 4°C. The pellet was washed with 1mL 70% (v/v) ethanol and spun 
down for 10 minutes at 13000xg. The final RNA pellet was dried in the hood and re-
suspended in 100µL water. 1 to 5ul of RNA was mixed with 2× RNA loading buffer and 
loaded to 10% urea gel to check the transcription efficiency. The gel was run in 1x TBE buffer 
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and stained with methyl blue. The RNA bands can be seen in blue after staining. After 
making sure that the product was as expected, the full RNA product was mixed with 2x RNA 
loading buffer and was loaded to 10% urea gel to run for 40 minutes at 300V. Target RNA 
band was cut out by using UV shadowing. The RNA gel was pushed through syringe to get 
small pieces. 1ml 0.3M sodium acetate pH 5.2 was added to the gel and kept at -20°C for 2 
hours. The gel was spun down at the maximum speed for 30 minutes and the supernatant 
was kept on ice. 1ml 0.3M sodium acetate pH 5.2 was added to the pellet gel again and the 
tube was kept at 37°C for 2 to 3 hours while shaking at 1000rpm. The gel was spun down at 
the maximum speed for 30 minutes and the supernatant was kept again. This RNA extraction 
process was repeated 4 to 5 times. RNA concentration was checked at every round, the 
extraction can be stopped if the concentration was very low. In the end, all the supernatants 
were pooled together and were precipitated with isopropanol (0.7 vol). The reaction was 
kept at -80°C for two hours and spun down at maximum speed for 30 minutes. The pellet 
was washed with 70% ethanol once, dried in the hood and dissolved in water. RNA aliquots 
were kept at -80°C ready for use. 
2.2.19 CPSF+symplekin complex preparation 
CPSF complex polymerase module and symplekin-CPSF100/73 complex were purified 
separately as the general His-MBP purification protocol (Supplementary Figure 3). After 
eluted from amylose column, the two sub-complexes were mixed, TEV and lamda 
phosphatase were added. The whole protein solution was transferred to SnakeSkin 7K 
MWCO dialysis bag and dialyzed to lysis buffer (with 1mM MnCl2 for lamda phosphatase 
activity) overnight. The protein was taken out from the dialysis bag the next morning and 
loaded to Histrap HP 5ml column equilibrated with lysis buffer. The protein complex bound 
back to the Ni column because the His-MBP tag on CPSF160 was not cleavable, while the 
SYMPK complex would come out from the flow through because the tag on SYMPK was 
cleaved nicely by TEV. The column was washed with lysis buffer till almost no protein coming 
out from the flow through (Using coomassie blue to track). Then the protein complex was 
eluted from the column with Ni elution buffer, together with TEV and MBP. In the later step, 
the target protein complex was concentrated with Amicon Ultra-15 centrifugal filter unit 
(100-kDa molecular mass cut-off) and loaded to Superose 6 increase 10/300 gel filtration 
column for size exclusion. TEV protease and lamda phosphatase can be removed in two 
processes: concentration and gel filtration, as the concentrator would keep only the proteins 
with the molecular weight of more than 100kDa, part of MBP and TEV can be removed in 
this step. The protein complex and TEV/MBP can be nicely separated by gel filtration 
because they have very big difference of molecular weight. 50ul of the peak fraction was 
dialyzed with Thermo Scientific Slide-A-Lyzer 20K MWCO MINI Dialysis Device for at least 4 
hours. The dialysis buffer was gel filtration buffer without glycerol and the target of dialysis 
was to remove the glycerol in the buffer. The ‘dialysis cup’ needs to be washed with ddH2O 
for 20 to 30 minutes before sample loading.  
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2.2.20 CPSF+SYMPK complex negative staining grids preparation and checking 
Before making cryo grids, the sample was normally checked by negative staining. For making 
negative staining grids, 2% uranyl formate (UF) solution was used. One big drop of ddH2O 
(1ml) and three drops of UF solution (25ul for each drop) were prepared on the plastic film. 
4ul of protein was applied to the glow-discharged side of the grid and kept on tweezer for 1 
minute, then the grid was washed with water for 1 minute with the protein drop side 
touching the water surface, the grid was taken out from the water drop and stained with the 
3 UF solution drops one by one (20 seconds each). Then the grid was kept on bench for one 
minute with the drop on. The drop was sucked from the other side of the grid with filter 
paper. The grid was kept on the bench for several minutes for drying and then transferred to 
the CM120 (Phillips) for checking. The negative staining grids can also be kept in the grid box   
for future screening (the storage of the grid should avoid light and can be stored maximum 
one month). Only samples with correct particle size and good distribution would be used for 
further cryo-EM analysis. 
2.2.21 CPSF+SYMPK complex cryo-EM grids preparation and data analysis with 
Glacios 
After dialysis, the concentration of the protein was normally diluted 2 to 3 times. The 
concentration of the gel filtration peak fraction was around 0.5mg/ml, after dialysis, the 
concentration was ~0.25mg/ml, which was a proper concentration for cryo grids making.  
QUANTIFOIL Au 2/2 grids were used for freezing. After glow discharge, 4ul of sample was 
loaded to the glow discharged side of the grid, after waiting for 10 seconds, the grid was 
blotted for 8.5s with blotting force 6 and dropped into liquid ethane. The grids were 
prepared by using Vitrobot Mark IV (FEI, Hillsboro, OR). The temperature of the Vitrobot 
chamber was set to 4°C and the humidity with 100%. The grid was kept in liquid nitrogen and 
screened with Glacios (Thermoscientific). Grids with thin ice and good particle distribution 
were used for further data collection. 
Initial cryo-dataset was collected with Glacios operated at 200keV and equipped with 
Falcon3 camera. Micrographs were collected automatically with the software package EPU 
(FEI) at the magnification of 120K (1.23 Å per pixel) in linear mode. The dose rate was 
45.17e−/pixel/s. three images were acquired per foil hole. Each micrograph was collected 
with a total dose of 29.86 electrons per square angstrom over a 1.52s exposure, fractionated 
into 30 frames. Defocus values ranged from 1.25 to 3μm. Warp (Dimitry Tegunov, 2018) was 
used for micrograph alignment, motion correction and CTF correction, as well as particle 
picking. The data processing was performed using cryoSPARC (Punjani et al., 2017). 
 
2.2.22 CPSF+SYMPK complex Titan Krios data collection and processing  
The data was collected on a FEI (Thermo fisher Scientific) Titan Krios, operated at 300 keV, 
and equipped with a Gatan K3 Summit direct electron detector and a Quantum GIF. 
Micrographs were collected automatically with the software package Serial EM 
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(Mastronarde, 2003) at a nominal magnification of 81K (1.05 Å per pixel) in counting mode. 
The dose rate was 30.25e−/pixel/s. Three images were acquired per foil hole. Each 
micrograph was collected with a total dose of 27.5 electrons per square angstrom over a 
1.491 exposure, fractionated into 40 frames. Defocus values ranged from 1 to 3μm. 
Micrograph frames were aligned and corrected with Warp (Dimitry Tegunov, 2018), CTF 
correction and particle picking were also performed with Warp (Dimitry Tegunov, 2018). 
Initial data analysis was performed with cryoSPARC (Punjani et al., 2017), while further data 
processing was performed with RELION 3.0.6 (Zivanov et al., 2018).  
2.2.23 CstF complex crystallization  
CstF complex was expressed in insect cells and purified as the normal purification protocol 
(Supplementary Figure 3). The protein was concentrated to 10mg/ml, 200ul was taken out 
and kept on ice. Then the rest was concentrated to 20mg/ml. Both samples were sent for 
setting up drops. The drops were set up with Gryphon crystallization robot on intelli plates. 
12 commercial crystallization Kits were used, which includes 9 from QIAGEN (AmSO4, 
Classics, Classics II, Classics Lite, JCSG+, PEG, PEGs II, pHclear, pHclear II), 2 from JENA BIO 
SCIENCE (Wizard 1+2, Wizard 3+4) and 1 from HAMPTON RESEARCH (Index). The drops were 
checked with Rock imager. The crystals were picked out from the drop, flash-frozen into 
















3.1 Purification of termination/3' processing factors (subcomplexes) 
Based on current literature, the factors were purified as part of multi-subunit complexes.  
Five well known complexes were expressed in insect cells and purified following the 
purification flowchart (Supplementary figure 3), which includes the Pcf11-Clp1 (CFII) 
complex, CPSF polymerase module, CPSF nuclease module with symplekin, CstF complex and 
CFIm68/25 (CFI) complex. CFII and CstF complexes were initially designed as one complex 
based on the study in yeast, in which Rna14-Rna15-Pcf11-Clp1 form the CFIA complex 
(Gordon et al., 2011).  In this combined construct all subunits were combined in one vector 
and either CstF77 or Pcf11 was tagged. However, such approach was not successful because 
only subcomplexes containing the tagged subunits could be purified (data not show), this 
was also shown in early studies (Takagaki et al., 1989). Thus, CFII and CstF complexes were 
redesigned and purified separately. One of the subunits of the complex was tagged with the 
His-MBP at the N-terminus. A TEV site was added between the target protein and the His-
MBP tag to make sure the tag can be removed in the final purification step. However, the 
cleavage site was not exposed at the surface of the structure, which made the cleavage 
difficult, such as the case when the tag was installed on CPSF160. Pcf11, CstF77, CPSF160, 
SYMPK and CFIM68 were tagged in corresponding complex CFII, CstF, CPSF polymerase 
module, CPSF nuclease module and CFI respectively. The tag on PCF11 was cleavable, but 
the protein was still bound back to the Ni column during the reverse nickel step, maybe 
because of some internal Ni binding sequences. The protein was eluted from the Ni column 
together with MBP and TEV, however, MBP and TEV were removed by gel filtration 













Figure 2.4: Purification of termination/3’ processing complexes. A, Purification of CPSF 
polymerase module, chromatogram of gel filtration is shown on the left and SDS-PAGE gel is 
shown on the right (this is consistent in B, C, D and E). The target protein peak and subunit 
names are marked. CPSF160 was tagged with his-MBP at the N terminus but the tag was not 
cleavable. B, Purification of symplekin-CPSF100/73 complex. Symplekin was tagged at the N-
terminus and the tag was removed after the reverse Ni step. The shoulder of the peak might 
come from protein aggregation. C, CstF complex purification, CstF77 was tagged at the N-
terminus and the tag was cleavable. D. CFIm68/25 complex. Superdex 75 column was used 
for gel filtration because of better resolution. CFIm68 was tagged and the tag was cleavable. 
E, Purification of Pcf11/Clp1. Pcf11 was tagged, the protein bound back to Ni column even 
though the tag was cleavable (right panel). So there is one peak after the main peak, which 




3.2 CPSF polymerase module and nuclease module containing 
symplekin form a stable complex  
After purification of the complexes, both pull down and gel filtration were executed to check 
the interactions between different complexes. By checking the interactions, I investigated 
which complexes are stable enough for structure analysis. After the initial screening, I 
managed to assemble the full CPSF complex containing the symplekin. CPSF polymerase 
module and nuclease module plus symplekin formed a stable complex both on the gel 
filtration column and the sucrose gradient (Figure 2.5). This was verified at least three times. 
In gel filtration, the complex peak shifted to the earlier volume compared with the sub-
complex peak. In sucrose gradient, there is also a clear shift on the native gel (Figure 2.5B, 
right panel) 
           A 
 
 
Figure 2.5: CPSF polymerase module and nuclease module plus symplekin form a stable 
complex. A, the complex peak is in yellow, polymerase module peak is in blue and nuclease 
peak is in red. The SDS-PAGEs are shown next to the corresponding peaks and the subunits 
are marked. A truncated version of WDR33 (residue 1 to 572) was expressed in the 
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polymerase module. B, Sucrose gradient diagram (left panel) and corresponding native gel 
(right panel). The polymerase module and the nuclease module alone were detected in the 
upper fractions whereas the complex formed by the two modules was detected in the 
bottom fractions. Proteins at the very bottom might be aggregated proteins. 
3.3 Initial cryo-EM structure analysis of the CPSF-symplekin complex 
with Glacios 
The grids with CPSF-symplekin complex were screened with Glacios. Grid with proper ice 
thickness and nice particle distribution was used for overnight data collection. 85,216 
particles were picked with Warp (Dimitry Tegunov, 2018) with a box size of 330 pixels from 
the overnight dataset (Figure 2.6A). 2D classification was executed several rounds to remove 
the bad particles with cryoSPARC (Punjani et al., 2017) (Figure 2.6B). After 2D classification 
sorting, 68,513 particles were extracted for further processing. Ab-initio reconstruction gave 
out 3 initial models. These three maps were refined individually with the cryoSPARC 
‘Homogeneous refinement’ function. One class that includes 31.4% particles showed extra 
density in addition to the polymerase module (Figure 2.6C). The resolution of this map 
calculated by cryoSPARC was 8.37Å, however, upon visual inspection it was obvious that the 
map looks worse than 8.37Å and the resolution might be overestimated by cryoSPARC. Even 
though the resolution was not as high as cryoSPARC estimated, structure of the CPSF 
polymerase module (PDB 6BM0)(Sun et al., 2018) could be fitted into the density map 
unambiguously. The extra density was quite obvious even at low threshold. It was difficult to 
assign the extra density to the additional subunits at this resolution. However, since the 
particles aligned well both in 2D and 3D and at least one third of the particles contained the 
additional density aside from the polymerase module, I attempted to improve the resolution 




Figure 2.6: Initial cryo-EM data analysis of CPSF-SYMPK complex. A, Typical micrograph, 
particles are highlighted with green circles. B, Part of the 2D classes from data processing, 
classes contaminated with gold particles were discarded before another round of 2D 
classification. C, Three different views of the 3D map which showed extra density in addition 
to the polymerase module. The 3D map was created with Ab-initio reconstruction and 
refined with homogeneous refinement in cryoSPARC. Structure of the CPSF polymerase 
module (PDB code 6BM0 (Sun et al., 2018) in color purple) was fitted into the density map 
(cyan). 
3.4 CstF complex crystallization  
The yield of CstF complex expression in insect cells was very good. Around 20mg of protein 
can be purified from 1 liter of hi5 cells. The purity of the complex was also suitable for a 
crystallization trial (Figure 2.7B). For the first screening, there were needle crystals in several 
conditions (Figure 2.7C). These conditions contained 100mM Tris or Hepes (pH from 7.0 to 
8.0) and the precipitant of different molecular weights of PEGs (Figure 2.7C). However, even 
more conditions were set based on the initial conditions, the diffraction of the crystals was 
not improved at all. Some more optimization is necessary to improve the diffraction of the 




Figure 2.7: Purification and crystallization of CstF complex. A, cartoon showing the position 
of CstF complex in the termination machinery. CstF exists as a heterodimer and binds 
specifically to the pre-mRNA DSE in the 3’ processing/termination complex. B, gel filtration 
chromatogram of CstF complex and the corresponding SDS-PAGE gel. The protein purity was 
reasonable for crystallization. C, initial crystallization screening with the commercial kit. Left 
panel: 12% PEG4000, 100mM Hepes pH7.5, 100mM sodium acetate trihydrate. Crystals 
appeared after 3 days. Right panel: 10% PEG6000, 100mM Hepes pH7.0. Crystals appeared 










4 Discussion and future perspectives 
4.1 CPSF-symplekin complex - structure and function 
4.1.1 First data collection and analysis with Titan Krios  
After initial analysis of Glacious data, a dataset from Titan Krios was collected with Serial EM 
and K3 camera (Gatan). In 64 hours, 8,651 micrographs were collected, and around 1.83 
million particles were picked with Warp from these micrographs. The particles were re-
extracted with RELION3.0.6 (Zivanov et al., 2018) with 2 times binning. All the processing 
was executed with RELION3.0.6. The extracted particles were submitted for 2D classification 
and the ‘bad’ classes (classes with gold particles or fussy looking ones) were sorted out. 
Particles in the good classes were saved and used for the second round of 2D classification. 
This process was repeated several times till the particle set was ‘clean enough’. Then the 
good particles were used for further processing. There are several ways to get an initial 
model: calculating the initial model with RELION with the particles from the same dataset, 
using the model obtained from the Glacious dataset (the one shown in Figure 2.6) or using 
the lowpass filtered human polymerase module map (EMD-7112)(Sun et al., 2018). All these 
three models were used for 3D classification to see which works best, and the initial model 
built by RELION was finally picked for further processing because upon visual inspection it 
looked better than the other two. However, in the later 3D classification and 3D refinement 
process, the particles showed strong preferred-orientation. Because the information on the 
missing views was lacking, it was difficult to improve the resolution of the density map. Thus, 
to improve the density map, the quality of the dataset itself should be improved. The 
angular distribution diversity can be changed by either tilting the sample stage for a defined 
degree or by influencing the particle distribution biochemically. Tilting the sample stage to 
get the lost orientations is normally the first thing to try, because this microscopy setting is 
easy to manipulate and it is not a very time consuming process. The second method is to 
chemically crosslink the sample prior to grid preparation or to add detergent to the sample. 
This may lead to a more diverse angular distribution. The advantage of the second method is 
that it can solve the problem fundamentally, but the disadvantage is that it is more 
complicated because we are not sure which kind of crosslinker or detergent would work, and 
normally a lot of biochemistry experiments need to be done before an improvement can be 
made. Considering all these issues, we decided to collect another dataset by tilting the stage 
for 35 degrees in hope to capture the missing particle orientations.  
4.1.2 Tilt data collection with Titan Krios and analysis  
The settings for tilt data collection were the same as the first Titan Krios dataset except that 
the sample stage was tilted for 35 degrees instead of keeping it at zero degree. The tilt data 
collection was performed for ~36 hours. The frame alignment, motion correction, CTF 
correction and particle picking were executed with Warp in parallel with the data collection. 
800,000 particles were picked in total by using Warp. The tilted particle dataset was 
combined with the original untilted particle dataset. The particles were re-extracted with 
RELION3.0.6. All the data processing was executed with RELION3.0.6. The angular 
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distribution diversity was improved a bit by combining the tilted and the untilted dataset (as 
seen from the angular distribution map, data is not shown), however, the processing is still 
on the way to improve the density map. The density around the polymerase part seems 
quite flexible, which made it difficult to improve, and also binding of the nuclease module 
might make the complex prefer to distribute as one orientation. Because from one of the 3D 
classes which includes only the polymerase module, it is reasonable to get a structure where 
the secondary structure is visible after 3D refinement, however, the 3D class with ‘extra 
density’ is tricky to be improved, maybe more focus classification (on the ‘extra density’ 
part) or refinement need to be done in the future. If the tilt dataset turns out to be not 
possible to get the structure, I would try to remake the grids. Maybe crosslinking with the 
sample would help. 
4.1.3 CPSF100 might work as the bridge between CPSF73, symplekin and the 
polymerase module  
The fresh CPSF-symplekin complex was sent for crosslinking MS analysis (it was done by Ralf 
Pflanz from Henning Urlaub lab) about the interactions between different subunits, 
especially the interaction between the known polymerase module and the unknown 
nuclease module. The crosslinking MS was repeated two times with different concentration 
of BS3 and DSS. From the result, I found that CPSF100 might be the bridge between the 
polymerase and nuclease module, because there are quite some crosslinks between 
CPSF160 and CPSF100 and also between WDR33 and CPSF100, even at very high threshold 
(Figure 2.8), for example the linking between CPSF160-Lys1420  and CPSF100-Lys450 and the 
linking between WDR33-Lys109 and CPSF100-Lys499. And these crosslinkings were very 
repeatable. I tried to map the crosslinking residues to the polymerase module and most of 
them were at the same side as the extra density (data is not shown), which means the 










Figure 2.8: Crosslinking MS result of CPSF-symplekin complex. A, crosslinking with 2mM BS3 
and 1mM DSS on ice for 2 hours for, B, crosslinking with 1mM BS3 and 0.5mM DSS on ice for 
1 hour. 
4.1.4 CPSF-symplekin complex cleavage activity  
CPSF73 is the endonuclease required for the pre-mRNA 3’ cleavage. It took a long time for 
the identification of the endonuclease responsible for 3’ cleavage. In 2006, the crystal 
structure of CPSF73 was solved by Tong lab (Mandel et al., 2006). In this work they defined 
CPSF73 as the endonuclease for pre-mRNA 3’ cleavage by both domain analysis and activity 
assays. In addition, they showed that the endonuclease activity of CPSF73 needs both Ca2+ 
and Zn2+. Before the activity assay, CPSF73 was incubated with 5mM Ca2+ for 30 minutes to 
be activated in vitro. However, this is a very high Ca2+ concentration compare to the 
concentration of free Ca2+ in mammalian cells, which is normally between 10 to 100nM 
(Milo, 2017). So it is not clear if the assay can represent the real case in the cells. In vivo, 
CPSF73 is part of the big 3’ processing machinery, the definition of the exact cleavage site 
and stimulation of CPSF73 activity might need more factors participating. In this work, 
CPSF73 was assembled into the whole CPSF complex together with symplekin and the 
complex was tested for pre-mRNA cleavage. In case the complex can indeed cleave the pre-
mRNA, several question follow: (i) what is the minimum complex which is active in 
cleavage?, (ii) is SYMPK-CPAF100/73 complex active?, (iii) which divalent ion is necessary for 
the cleavage? To answer these questions, I performed some very initial cleavage activity 
assays with purified components. While CPSF73 only and syplekin-CPSF100/73 complex had 
very weak cleavage activity, the CPSF-symplekin complex showed increased activity. Thus, 
even though the activity of the CPSF-symplekin complex was quite weak, it is much stronger 
than the activity of CPSF73 and the symplekin-CPSF100/73 complex alone (data is not 
shown). Different time points from 30 minutes to 2 hours were taken and no obvious 
differences were found between half an hour and 2 hours. 0.5uM Ca2+, Mg2+ and Zn2+ were 
used for the assay, respectively, and no difference was seen (data is not shown). This means 
if CPSF73 was assembled into the 3’ processing machinery, it might show some 
endonuclease activity, and whether divalent ion is necessary in endonuclease activity is not 
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clear. All these results need to be further verified by more experiments. The structural 
information might also help to clarify the cleavage activity in the future. 
4.2 CstF complex and DSE 
In this work, I managed to crystallize human CstF complex, which was thought as very 
flexible in early studies. However the crystals from the initial screening did not diffract at all. 
In the later work, I generated two strategies to improve the diffraction of the crystals: 
limited proteolysis and binding the protein with RNA. For limited proteolysis, the protein was 
incubated with different kinds of proteases respectively (Proti-Ace Kit - Hampton Research, 
protease to protein ratio 1:100) on ice overnight and then used for setting up drops. Crystals 
fished from one of the ‘clostripan digested’ drops showed some diffraction (~8 Å), however, 
the crystals need to be further improved. In the future, some constructs can be designed 
based on the previous experiments and secondary structure prediction. By cutting off some 
flexible loop inside the protein, hopefully the diffraction of the crystal can be improved. The 
limited proteolysis fragments can be sent for MS analysis to get some information for 
constructs design. Moreover, CstF works as a dimer in 3’ processing based on most of the 
literature, the question is: if CstF complex itself is organized as a dimer or it is organized as a 
dimer when associated with the 3’ processing machinery. If CstF complex itself is a 
heterodimer, then it might also be a good candidate for cryo-EM analysis. Because the 
molecular weight of the dimer is around 400 kDa, which is neither too small nor too big for 
EM structure analysis. However, maybe some strategies need to be taken to fix the flexibility 
problem. 
DSE is thought as the binding elements of CstF in canonical model. The conserved sequence 
YGTGTTYY (Y=pyrimidine) of DSE was defined in 1985 (McLauchlan et al., 1985) and the PAR-
CLIP data of CstF64 in 2012 showed the similar result (Martin et al., 2012). Based on these 
studies, two RNA fragments with different length and different sequences (CUGUCU and 
UGUGUUUU) were designed for CstF binding tests. Fluorescence anisotropy showed very 
weak binding affinity even with very low salt concentration buffer (Kd >1uM in 30mM NaCl 
buffer), the binding affinity of longer RNA is a bit higher than the shorter one (Kd ≈0.8uM) 
(data not show). This might imply that the binding of CstF complex to RNA depends more on 
the length of RNA instead of the sequence itself, or this might suggest that the binding of 
CstF to DSE is quite dynamic. In the future, maybe some studies can be done to detect the 
conserved RNA secondary structure around PAS site, because the secondary structure of 
RNA might be the target for the recognition of some protein factors. 
4.3 Human Pcf11 and termination 
In this work, I managed to purify the human Pcf11-Clp1 complex. So far this is the least well 
understood factor in mammalian 3’ processing complex. Most of the studies were about the 
yeast CFIA complex (Pcf11-Clp1-Rna14-Rna15). In yeast, Pcf11 has independent function in 
3’end processing and termination (Sadowski et al., 2003). It was shown to bind specifically to 
Ser2-P phosphorylated CTD peptides, the dephosphorylation of Ser2-P by some phosphatase 
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would lead to the dissociation of termination factors from CTD, which helps to regenerate 
the initiation competent Pol II (Meinhart and Cramer, 2004).  
Pcf11 in humans is twice as big as its yeast homolog and shares CTD-interaction domain at its 
N terminal. In this work, I purified the full length Pcf11-Clp1 complexe and was planning to 
assemble it to a Pol II termination complex which includes almost all the termination factors. 
However, recent study showed that Pcf11 might be a regulatory factor rather than a core 
subunit of the 3’ end processing, which means Pcf11 binds transiently to the complex 
(Kamieniarz-Gdula et al., 2019; Shi et al., 2009). However, as Pcf11 was shown to interact 
directly with Ser2-P CTD peptides in yeast, I think it is deserved to check the interaction 
between human Pcf11 and Ser2-P CTD peptides or the interaction between Pcf11 and Pol II. 
For the Pol II-Pcf11 interaction, the specific Ser2-P might be important. Very recently we 
found CDK12/CCNK has very specific Ser2 phosphorylation function, this might help us to 
form the ‘termination complex’ in the future. Because Pcf11 might be an important factor to 
connect termination and 3’ end processing. In the future, maybe some in vitro transcription 
and co-transcriptional 3’end processing experiment can be done to find the stable 
termination-3’ end processing complex which is suitable for structure analysis. 
4.4 CFIm68 and SR proteins  
The SR (Ser-Arg-rich) protein family is featured by an N termination RNA recognition motif 
(RRM) and a C terminal RS domain with variable length, RS domain is rich in arginine and 
serine (Sahebi et al., 2016). For some SR proteins, they have more than one RRM (Shepard 
and Hertel, 2009). SR proteins mainly function in pre-mRNA processing, especially for pre-
mRNA splicing. They also function in various post-splicing activities, which include mRNA 
nucleus localization, nuclear export and translation (Graveley, 2000; Sanford et al., 2004).  SR 
proteins interact with RNA simultaneously via its RRM and interact with other protein factors 
via the RS domain (Graveley et al., 1998; Wu and Maniatis, 1993). The phosphorylation 
regulation on serine of RS domain is an important process for the function of SR proteins. 
Both hyper- and hypo phosphorylated RS domain are unable to support splicing anymore 
(Graveley, 2000). SR proteins were first identified by the study of splicing in Drosophila (Tze-
Bin Chou, 1987). The definition of SR proteins is based on the presence of a phosphoepitope 
which can be recognized by the monoclonal antibody mAb104 and the conservation across 
vertebrates and invertebrates (Roth et al., 1990). There are nine members of human SR 
protein family which have similar structure organization (figure 2.9). Most SR proteins are 
enriched in nuclear compartments termed speckles, which can be seen throughout the 
nucleus (Lafarga et al., 2009). RS domain is responsible for targeting SR proteins to speckles 
(Spector, 1993). Recently, another group of proteins were found which have similar 
structure organization as SR proteins but might not be recognized by the monoclonal 
antibody mAb104. These proteins were named as SR-like proteins (Long and Caceres, 2009). 
CFIm68 (also named as CPSF6) is a typical SR-like protein with both the N terminal RRM and 
C terminal RS domain (Figure 2.8). CFim68 is involved in pre-mRNA 3' processing and binds 
specifically to the upstream sequence UGUA as mentioned before. The function of CFIm68 is 
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highly regulated by phosphorylation (Jang et al., 2019). In my purification, I was trying to 
purify CFIm68 and CFIm25 as a complex, CFIm68 was tagged at the N terminal with His-MBP 
tag and the complex was expressed in insect cells. Because insect cell expression might 
introduce some extra phosphorylation to the protein, normally we put lamda phosphatase 
to the overnight dialysis protein (the amylose elution protein with TEV) to remove the extra 
phosphorylation. However, I found a hydrogel inside the dialysis bag after overnight dialysis 
with TEV and lamda phosphatase. To figure out whether the phase separation was from TEV 
cleavage or from dephosphorylation, the protein was purified again following the same 
protocol and controls were set up for dialysis (TEV only, Lamda phosphatase only, none and 
both). I found that lamda phosphatase caused the phase separation because hydrogel was 
only found in the protein solution with lamda phosphatase but not in the TEV control (data is 
not shown). This means CFIm68/25 complex was phase separated after dephosphorylation. I 
repeated the experiment two more times and result was the same, which means this is 
really not an accident phenomenon and it deserves more attention. In later step, I checked 
the domain composition of both proteins and found that CFIm68 is a SR like protein and the 
dephosphorylation of RS domain might cause the phase separation. 
The crystal structure of CFIm68/25 was solved in 2011 (Yang et al., 2011), however the RS 
domain of CFIm68 was not included in the structure, maybe because the RS domain was too 
flexible and it was cut out for crystallization in this work. However, the RS domain might be 
an important domain for the function of CFIm68. Consistent with my speculation, recent 
studies showed that the phosphorylation state of CFIm68 is related with nuclear import and 
alternative polyadenylation (which would be discussed later(Jang et al., 2019). This study 
concluded that both the binding of CFIm68 to transportin 3 (TNPO3, a nuclear transport 
protein) and import to nucleus were independent of phosphorylation, but the 
hyperphosphorylated CFIm68 might lead to the failure of nuclear import. In addition to this 
study, very early literature also showed that the speckles in nuclear is not only an apartment 
of SR proteins and RNAs, but also a location for transcription factors and 3’ processing 
factors, which means the nuclear speckles might be a ‘processing factory’ of RNAs (Schul et 
al., 1998; Zeng et al., 1997). The concentrated factors in the compartment might make the 
RNA processing (including splicing and 3’ end processing) more efficient. However, more 
work need to be done in the future to clarify the function of the speckles and the 




Figure 2.9: SR protein family. There are 9 proteins in SR family which share the similar 
features with an N terminal RRM domain and C terminal RS domain. CFIm68 is a 3’ 
processing factor which shares similar feature with SR protein family and is named as SR-like 
protein. The figure was adapted from Shepard and Hertel: Genome Biology 2009. 
4.5 CFI complex and alternative cleavage and polyadenylation 
In more than 50% of human genes, pre-mRNA cleavage and polyadenylation can occur at 
multiple locations at the 3' end through a process called alternative polyadenylation (APA)                       
(Tian et al., 2005). APA is a co-transcriptional process that expands mRNA transcript 
diversity. There are two different types of APA based on the positional difference: In some 
cases, APA occurs inside the coding region which results in different protein isoforms, this 
type of APA is referred to as coding region APA (CR-APA); In other cases, APA sites are 
located in the 3' untranslated region (3' UTR), the coding region is the same but the length of 
UTR changes, which affects the expression efficiency of the protein, this type of APA is 
known as UTR-APA (Di Giammartino et al., 2011).  APA is highly regulated in different tissues 
and in tumorigenesis (Ji et al., 2009; Masamha and Wagner, 2018). The function of CR-APA is 
similar to alternative splicing, which also results in different isoforms of a protein, while 
regulation of UTR-APA is more complicated, as 3' UTRs often harbor microRNA (miRNA) and 
protein factors binding sites (Barreau et al., 2005; Fabian et al., 2010). Different lengths of 
UTRs affect not only the stability but also the transportation, localization and translational 
efficiency of mRNA. Transcripts with shorter UTR produce higher level of proteins (Mayr and 
Bartel, 2009; Sandberg et al., 2008), which normally happens in cell proliferation or in 
pathological cases like cancers, while in normal cell differentiation, 3' UTR tends to be longer 
(Ji et al., 2009; Wang et al., 2008).  
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Early studies showed that the knock down of CFI (either CfIm68 or CFIm25) leads to the 
shorter 3’ UTR (Martin et al., 2012; Masamha et al., 2014) and that CFIm functions as an 
enhancer dependent activator of mRNA 3’ processing (Zhu et al., 2018). Recent studies also 
showed that phosphorylation regulation of CFIm68 RS domain was important for the length 
control of 3’UTR (Jang et al., 2019). This study showed that the hypophosphorylated or 
physiologically phosphorylated RS domain of CFIm68 has normal binding affinity with 
TNPO3, which correlates with normal CFim68 nuclear import and distal or middle PAS usage 
(long 3’ UTR), while the hyperphosphorylated RS domain would cause the interaction defect 
of CFIm68 and TNPO3. The result is that CFIm68 cannot be imported to the nucleus, and the 
cells have to use CFIm59 as an alternative PAS recognition factor, which would lead to the 
proximal PAS usage and shorter 3’UTR. However, the clear mechanism for the long or short 
3’ UTR regulation is still not clear. In the future, more work should be done to figure out the 
detailed factors participation, interaction and regulatory mechanism. 
Even though APA was well studied during the last several years, we still have very limited 
knowledge about it. Further studies on the APA are required in the future, with a special 
emphasis on its regulatory function in tumorgenesis (Masamha and Wagner, 2018). 
4.6 Definition of the endonuclease for pre-mRNA cleavage 
Transcription is an important part of the central dogma in molecular biology. Since Pol II is 
responsible for the transcription of all protein coding genes, its structure has been studied 
for many years. In 2000, the first Pol II structure was solved (Cramer et al., 2000), which 
opened the door for the structural study of transcription. Perhaps because of its foremost 
position in the transcription cycle, transcription initiation was quite well studied, including 
the promoter recognition, binding of initiation factors and Pol II, DNA opening and synthesis 
of the initial RNA (8~9 nucleotides). More recently, the transition phase in the transcription 
cycle between the initiation and elongation (also known as the promotor-proximal pausing), 
was structurally characterized (Vos et al., 2018a; Vos et al., 2018b). However, transcription 
termination is the least known process in the whole transcription cycle. The regulation of Pol 
II termination is an important process because it defines the boundaries of the transcription 
unit and avoids the interfering of transcription between different genes. More importantly, 
termination guarantees that the Pol II can be recycled timely for the initiation of a new 
round of transcription. 
Pol II termination was well studied in yeast for both non-coding RNAs and mRNAs. There is a 
big machinery which is responsible for termination and mRNA 3' processing both in yeast 
and in humans. As the cleavage of pre-mRNA is an important step in polyadenylation and 
maybe also in termination, scientists put a lot effort to figure out which endonuclease is 
responsible for the pre-mRNA cleavage. In 2006, Tong. L and colleagues solved the structure 
of human CPSF73 and yeast CPSF 100(Mandel et al., 2006). They defined CPSF73 as the 
endonuclease based on the structure analysis of the active site and sequence analysis. 
However, they also showed that CPSF73 can only exhibit its endonuclease activity, along 
with exonuclease activity, after incubating with Ca2+ at 37°C for half an hour. However the 
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concentration of Ca2+ they used for assay is much higher than the concentration 
physiologically, so there must be some other mechanisms and protein factors which function 
to stimulate the nuclease activity of CPSF73 and to define the exact cleavage site in vivo. 
Very recently, In March of 2019, Lori A. Passmore and her team defined the 8-subunit core 
that is necessary for the activation of endonuclease in pre-mRNA 3' end processing in yeast 
(Hill et al., 2019). The 8-subunit core includes Ysh1, Cft2, Mpe1, CFIA, a complex of Rna14, 
Rna15, Pcf11 and Clp1 and CFIB (Hrp1), which was named CPF core. After association with 
the CPF core, Ysh1 was active to cleave the pre-mRNA at the cleavage site in vitro. The 
corresponding factors for Ysh1 and Cft2 in human are CPSF73 and CPSF100 respectively. For 
CFIA, there are two sub-complexes in human, which are CstF complex and CFII (Pcf11 and 
Clp1). CFIB corresponds to CFI (CFIm68/25) complex. Even the 3' processing factors are 
highly conserved in yeast and human. There are some differences, for example, as 
mentioned before, CFIA complex is composed of Rna14, Rna15, Pcf11 and Clp1 in yeast, 
however the homolog CstF complex and Pcf11/Clp1 did not prefer to form a complex in vitro 
from my all my eperiments. They have no interactions in my assays. RBBP6, the human 
homolog of Mpe1, was not well studied, even though Mpe1 is a very important factor for the 
pre-mRNA cleavage in yeast. Also, symplekin forms a stable complex with CPSF100 and 
CPSF73 in our work. The corresponding protein factor of symplekin in yeast is Pta1, which 
fell off the CPF core and didn’t show much importance in cleavage (Hill et al., 2019). In the 
future, more work should be done to figure out the corresponding ‘CPF core’ in humans. 
In this work so far, I managed to reconstitute the whole CPSF complex plus symplekin, which 
includes CPSF160, CPSF100, CPSF73, WDR33 (1-572aa), CPSF30, Fip1 and symplekin. The 
symplekin-CPSF100/73 complex was purified first and then combined with CPSF complex 
polymerase module. As discussed before, CPSF73 shows some endonuclease activity when 
assembled in the whole complex. However, it is still uncertain if the CPSF complex combined 
with the symplekin is sufficient for the full pre-mRNA cleavage activity or additional factors 
also play a role. Hopefully further biochemical and structural studies can offer more insights 
into this question. 
4.7 Future perspectives 
4.7.1 Termination pausing and the disengagement of Pol II from template DNA 
The promoter-proximal pausing is well known and studied as introduced in chapter 1. 
However, there is another pausing, which occurs when Pol II transcribes over the poly(A) tail, 
is not so well studied. Whether pausing is a prerequisite for termination is still under debate 
in both yeast and mammals (Creamer et al., 2011; Plant et al., 2005). So far only two 
sequences were discovered to function in termination pausing: The MAZ element which is 
found in liver-specific C2 complement gene and featured with the sequence G5AG5 (Ashfield 
et al., 1994), and CCAAT-box which was found in the adenovirus (Connelly and Manley, 
1989). Pausing was thought to occur before termination when Pol II slows down at the 
termination region. One explanation is that pausing after transcribing over poly(A) signal 
gives enough time for either the catching up of XRN2 (torpedo model) or the exchange of 
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elongation factors to termination factors (allosteric model)(Glover-Cutter et al., 2008). If this 
is the hypothesis, then what is the driving force for pausing and how is the paused 
elongation complex (EC) released? All these questions need a further study in the future. For 
now the hypothesis might be that the CPSF complex is bound with elongation complex 
during elongation and ‘scans’ for the termination signal, once EC ‘walks’ over the 
termination signal, CPSF would bind specifically to both pre-mRNA PAS site and Pol II and 
cause the initial pausing, then the binding of the other termination factors like CstF would 
stabilize the pausing. The release of Pol II from template DNA might need more 
interactions/competition between different factors or Pol II (Nag et al., 2007) and the 
regulation of kinase/phosphatase of both CTD and termination factors, just like the 
promoter-proximal Pol II release (Vos et al., 2018a). However, the hypothesis needs to be 
verified in the future by more experiments. The cleavage of pre-mRNA is a prerequisite for 
allosteric model, so figuring out the relationship between pre-mRNA cleavage and 
termination might help for getting the correct termination model. 
4.7.2 Termination and re-initiation 
In a simplistic view, a gene is a linearized DNA sequence with a promoter at one end and 
terminator at the other end. In transcription, Pol II initiated from promoter with the help of 
general factors and terminates at the end of the gene with the termination factors binding. 
After releasing from the template DNA, Pol II was recycled and the new transcription started 
(Fuda et al., 2009)(Figure 2.9A). However, in the real cells, it is much more complicated. The 
main question for this simplified model is how efficient Pol II can be recycled, because there 
is a big space gap between promoter and terminator. Further studies showed that 
termination and initiation have a crosstalk based on several discoveries. The first finding is 
that mutation of poly(A) site impaired termination and also decreased the initiation of the 
same gene, which implies a relationship between termination and re-initiation, and also the 
mutation or deletion of termination factors impairs the initiation (Mapendano et al., 2010). 
The second interesting observation is the direct interaction between initiation factors and 
termination factors, like the interaction between TFII D and CPSF (Dantonel et al., 1997), the 
binding of phosphorylated TFII B and CstF complex (Wang et al., 2010). Both these 
observations imply that initiation and termination didn’t occur independently, they must 
have a crosstalk to make the transcription more efficient. The question is, how? There are 
three putative models so far. The first, also the most widely accepted model, is the gene-
looping. The hypothesis is that the promoter and terminator of the same gene have direct 
physical contacts or at proximity via initiation or termination factors, which ensured that the 
released Pol II can be recycled efficiently for the re-initiation (Figure 2.9B)(El Kaderi et al., 
2009; Hampsey et al., 2011; O'Sullivan et al., 2004). By using the method of chromosome 
conformation capture (3C) method (Tolhuis et al., 2002), the study showed that the gene 
loops are dynamic structures which form upon transcription. The formation of the gene 
loops need the interaction of initiation factor TFIIB and termination factors Pta1 and CPF, the 
interaction was regulated by the phosphatase SSu72 (Hampsey et al., 2011). The second 
possibility is that the active genes are positioned in a sub compartment, where both Pol II, 
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initiation and termination factors are highly compacted, which makes the transcription and 
Pol II cycling much more efficient (Osborne et al., 2004; Yao et al., 2007)(Figure 2.9C). These 
sub-compartments are membraneless organelles which are formed by phase separation. The 
most well-known membraneless organelle is the nucleolus. In recent years, phase separation 
was also found in transcriptional regulation (DenesHnisz, 2017). However, even this theme 
has been demonstrated in several organisms, its study is still at the very early stage. Maybe 
in the future, more phase separation study of Pol II and transcription would offer more 
evidence knowledge for this theme. Thirdly, the termination and initiation might occur in 
long distance but they communicate via extra signals like chromatin structure, chromatin-
associated factors or some small non-coding RNAs (Figure 2.9D). In some early studies, 
people even assumed that the terminator might work as a promoter or vice versa. I 
speculate that all the transcription and RNA processing factors might concentrate in one 
compartment in the nucleus, which makes the transcription and pre-mRNA processing much 
more efficient. However, the gene looping is also necessary for efficient transcription. In the 
future, more work can be done for the ‘transcription efficiency’ study. 
4.7.3 Termination is a regulatory way for gene expression 
Termination is not only a way for genomic partitioning, but also a regulatory mechanism for 
gene expression. Instead of the conventional concept that transcription starts from 
promoter and ends at terminator, recent studies showed that the genome is highly 
transcribed, even the non-coding area. The entirely transcription needs some ways for 
regulation, termination is one way. Termination occurs not only at the end of one gene but 
also the beginning and middle of the ORF, which is an important way for transcription 
regulation. The typical example for termination regulation is the clusters of amino acid 
biosynthesis genes in bacteria (Merino E, 2005), which is named as premature termination. 
When enough amino acids exist in the cells, a termination complex would form at the 5' 
UTR, which would release Pol II from the template DNA before it going to the protein coding 
region. The regulation complex is normally composed of protein factors and some non-
coding RNAs (Naville and Gautheret, 2010). Premature termination or attenuation was also 
discovered in virus or eukaryotic organisms and was thought as a widespread regulatory way 
(Kim and Levin, 2011). Defective termination affects both co-transcriptional splicing and RNA 
synthesis and stability. In the future, more study can be focused on the early termination 




Figure 2.10: Hypothesis for efficient termination and re-initiation. A, Classical linear 
initiation and termination, the polymerase cannot be recycled efficiently. B, gene looping 
brings promoter and terminator closer, which is more efficient for transcription. C, there are 
a lot of factors and polymerase in the small compartment, which made the re-initiation more 
efficient. D, the gene itself is linear but the initiation and termination have some crosstalk via 







Supplementary Figure 1: LIC cloning flowchart, adapted from MacroLab_Vectors_v8 April 3, 
2014. A, the linearized vector and PCR product were treated with T4 DNA polymerase 
separately with corresponding dNTPs (dCTP or inserts and dGTP for vector) to generate the 
overhangs for annealing. The nicks after annealing can be repaired by E.coli cells after 
transformation. B, the acceptor and doner vector were digested with SwaI and PmeI 
respectively. The ‘LIC’ method was used again for the ligation and the annealed vector was 




Supplementary Figure 2: Protein expression in insect cells. V0, V1 and V2 (or expression) 
are made with sf9, sf21 and hi5 cells respectively. Cells should be checked every day to keep 








Supplementary Figure 3: Protein purification flowchart by His-MBP tag. The supernatant 
from the lysate was loaded with peristaltic pump, the wash and elution of both Ni column 
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